Medication safety devices and methods

Information

  • Patent Grant
  • 10881784
  • Patent Number
    10,881,784
  • Date Filed
    Tuesday, July 28, 2015
    9 years ago
  • Date Issued
    Tuesday, January 5, 2021
    3 years ago
Abstract
A medication safety device and method can include an infusion pump and a drug library in communication with the infusion pump. The drug library can have upper hard and soft limits and lower hard and soft limits associated with at least one drug. A graphical user interface can display a bar chart showing upper and lower soft limit bars for the at least one drug. The upper and lower soft limit bars can be grabbed and dragged on the graphical user interface in touch-screen fashion to new positions associated with new upper and lower soft limits. The graphical user interface and associated hardware and software can be configurable to responsively re-analyze data and compare a particular infusion to the new upper and lower soft limits.
Description
TECHNICAL FIELD

This disclosure relates generally to medical systems, devices, and methods for facilitating the safe delivery of medication. In particular, it relates to systems, devices and methods for the operation of medical infusion pumps, and for the development and maintenance of drug libraries used in the operation of such pumps.


BACKGROUND

Medical infusion pumps are used to infuse liquids, such as nutrients and medicaments, into the circulatory system of a patient. Such pumps provide a wide range of flexibility in administering such fluids. For instance, the rate at which a medicament is introduced into the circulatory system can be variably programmed, the total volume to be administered can be pre-set, and the time for administering the medicament can be scheduled for automatic delivery at a certain periodicity. While the pre-programming of infusion rates, times and amounts with infusion pumps enables a wide variety of treatment protocols that would be impractical, expensive or unreliable if performed manually, it also presents the challenge of safely controlling the introduction of fluids into a patient when medical personnel are not continuously present.


Medical infusion pumps can be classified as large volume or small volume. Large volume pumps are typically used for medications and fluids, such as nutrients, that need to be delivered to patients in relatively large volumes compared to other medications and fluids, while small volume pumps can be used to infuse insulin or other medicines such as opiates. While small volume pumps can take different forms, syringe pumps are one of several types of pumps that can provide precision infusion of small amounts of fluid.


A syringe pump typically employs a pre-filled medication syringe that is mechanically driven under microprocessor control to deliver a prescribed amount or dose of a fluid at a controlled rate to a patient through an infusion line fluidly connected to the syringe. Syringe pumps typically include a motor that rotates a leadscrew. The leadscrew in turn activates a plunger driver which forwardly pushes a plunger within a barrel of the syringe. Pushing the plunger forward thus forces the dose of medication outwardly from the syringe, into the infusion line, and to the patient—typically, intravenously. Examples of syringe pumps are disclosed in U.S. Pat. No. 4,978,335 titled “Infusion Pump with Bar Code Input to Computer”, U.S. Pat. No. 8,182,461 titled “Syringe Pump Rapid Occlusion Detection System”, and U.S. Pat. No. 8,209,060 titled “Updating Syringe Profiles for a Syringe Pump,” each of which is incorporated herein by reference in its entirety. As used throughout this disclosure, the term “syringe pump” is intended to generally pertain to any device which acts on a syringe to controllably force fluid outwardly therefrom.


Syringe pumps are used to control delivery to a patient of medications or fluids that include, but are not limited to: therapeutic agents; nutrients; drugs; medicaments such as antibiotics, blood clotting agents, and analgesics; and other fluids. The devices can be used to introduce the medications or fluids into the body of a patient utilizing any of several routes such as, for example, intravenously, subcutaneously, arterially, or epidurally.


To enhance patient safety during infusions, syringe pump manufacturers have developed so-called “smart” pumps that may provide functionality beyond just the delivery of fluids to a patient by the aforedescribed mechanical means. Smart pumps typically provide information concerning, or might even impose, safety limits on medication program parameters such as dose, concentration, and time, etc., for delivery of a particular medication from the pump to a particular patient. Consequently, more work may be required from practitioners to create and maintain so-called “drug libraries” associated with such safety limits. Provision of such functionality may be considered as being of higher importance in certain practices, protocols, and standardized procedures. There may be not as much emphasis or need for standardization, provision of pump safety limits, or restrictions on medication dosing rate ranges, however, with other practices and protocols. Thus, there is an unmet need for pumps that provide several levels of functionality.


In settings that typically do not require a high degree of functionality with safety limits and/or drug libraries for pumps, practitioners are usually accustomed to workflows that are much simpler than those of smart pumps. A simple workflow is usually defined as “Rate, Volume, Run” or a similar, basic controlled infusion protocol. Conversely, a more fully controlled infusion would typically employ applicable safety limits, which are commonly referred to as “hard” and “soft” limits, on delivery of a particular medication. A hard limit is often defined as a limit for which a selected infusion parameter that is outside of the limit results in generation of an alert and rendering of the pump inoperative or unable to accept selection or input of the parameter. Hard limits are typically set for high-risk drugs such as heparin. A soft limit, however, is often defined as a limit which may generate an alert but still may be overridden so that the infusion may proceed. When hard and/or soft limits are employed with a smart pump, information is usually input to the pump—or another system in communication with or controlling the pump—which includes data such as patient weight, the type of medication being infused, and the prescribed drug concentration. Typically a drug library contains a list of medications at predefined or standard concentrations, which in turn effectively determines safe dosing ranges. To program such a smart pump with a drug library, the practitioner would typically need to select the particular medication and concentration, enter the patient's weight, program the required infusion parameters such as dose and time, and then enter a command to start the infusion. These steps result in a more complicated workflow for practitioners.


Perhaps a larger challenge to smart pump workflows, however, is in preparing and setting running parameters, etc., before actual use of a pump with a patient. A clinical staff member such as a pharmacist would most likely need to develop a drug library with hard and soft limits for each medication and possibly for each drug concentration as well. In some cases these drug libraries or lists may exceed thousands of entries that need to be defined and entered prior to patient infusions. Developing and maintaining a drug library requires the management of a large number of drug lists, a large amount of hand-entered data, and therefore, involves a considerable amount of time. This problem is exacerbated in any transition to or from the traditional drug library storage component as part of a Hospital Information System (HIS).


It would therefore be useful and advantageous to provide medication safety devices and methods which would meet the needs of both a high and a lower functionality in setting limits and in drug libraries, and which could easily transition from a low functionality to create and maintain a more sophisticated drug library if desired.


SUMMARY

Embodiments of the disclosure provide novel and inventive medication safety devices and methods.


In an embodiment, a medication safety device can include a pump and a drug library in communication with the pump. The drug library can have upper hard and soft limits and lower hard and soft limits associated with at least one drug. A graphical user interface can display a bar chart showing upper and lower soft limit bars for the at least one drug. The upper and lower soft limit bars can be grabbed and dragged, in one particular embodiment, on the graphical user interface in touch-screen fashion to new positions associated with new upper and lower soft limits. The graphical user interface and associated hardware and software can be configurable to responsively re-analyze data and compare a particular infusion to the new upper and lower soft limits. Therefore, in a feature and advantage of various embodiments, user-interactive limiting values are implemented on a drug library for a syringe pump. For example, a slidable Lower Soft Limit (LSL), Upper Soft Limit (USL), Lower Hard Limit (LHL), and/or Upper Hard Limit (UHL) can be utilized to group and ungroup data in the drug library data sets to present limits in relation to known prior infusions. Clinicians or review boards can therefore readily examine the effect of the change to the limits on the number of acceptable and unacceptable infusions falling on some aspect of the LSL, USL, LHL, and/or UHL, or the capability index calculated. Embodiments therefore offer a holistic approach to the creation and maintenance of drug libraries.


In an embodiment, a method of creating a drug library comprises receiving a drug list, the drug list including a plurality of listed drug names, one or more delivery concentrations for each of the listed drugs, and one or more dose rates for each of the listed drugs, receiving operational data from at least one infusion pump, the operational data including information related to an infusion by the at least one infusion pump of at least one of the plurality of listed drugs, and integrating the drug list and the operational data.


In an embodiment, a medication safety system comprises at least one infusion pump, and an aggregating server operably coupled to the at least one infusion pump, the aggregating server comprising a processor and memory and configured to: receive a drug list, the drug list including a plurality of listed drug names, one or more delivery concentrations for each of the listed drugs, and one or more dose rates for each of the listed drugs, receive operational data from the at least one infusion pump, the operational data including information related to an infusion by the at least one infusion pump of at least one of the plurality of listed drugs, and integrate the drug list and the operational data to create a drug library.


In an embodiment, a method of transitioning an infusion pump comprises operating the infusion pump in a rate-volume-run mode, operating the infusion pump in a data-gathering mode, and operating the infusion pump in a smart-pump mode.


In an embodiment, an infusion pump comprises a pumping mechanism and a processor configured to operate the infusion pump in a rate-volume-run mode, operate the infusion pump in a data-gathering mode, and operate the infusion pump in a smart-pump mode.


In another feature and advantage of various embodiments, capability indices can be applied to drug library data sets to group and ungroup data in the data sets. For example, a change to the process capability index can automatically create a new chart for comparison having new boundaries or potential limits. Clinicians or review boards can therefore readily examine the affect of the change to the process capability index on the number of acceptable and unacceptable infusions falling on some aspect of the LSL, USL, LHL, and/or UHL.


In another feature and advantage of various embodiments, the user interface described herein can be presented on an operably coupled server, on an integrated viewing device, or on a particular pump. For example, an aggregating server can be operably coupled to one or more pumps, as will be described, for data-gathering utilizing one or more “data gathering” pumps. The aggregating server is configured to receive data from the one or more data gathering pumps and collect or aggregate said data for inclusion in drug library data sets. Thereafter, the user interface presenting drug library and limiting bars can be displayed on the aggregating server for limiting or other data set manipulation and analysis. In another example, the server can aggregate the data as described above, but particular limiting or other data set manipulation and analysis can be conducted on an integrated viewing device operably coupled to the aggregating server, such as a computer, tablet, smartphone, PDA, or other suitable device. In another example, the server can aggregate the data as described above, but particular limiting or other data set manipulation and analysis can be conducted on a pump or other medical device operably coupled to the aggregating server. In embodiments, the pump is the data gathering pump that transmitted infusion data to the aggregating server. In other embodiments, an individual pump can function as the aggregating server.


In another feature and advantage of various embodiments, dynamic data management is provided. In an embodiment, the data aggregated and/or presented can be filtered for patient populations, for example, pediatric patients, geriatric patients, high-risk patients, or low-risk patients, etc. Once aggregated, the data can be filtered according to input from the clinician, review board, or other user. For example, the appropriate limiting for pediatric patients can differ greatly from the limiting for adult patients. Therefore, it may be prudent to provide different upper and lower limits for these populations. Likewise, the limiting appropriate for high-risk adult patients can differ greatly from the limiting appropriate for low-risk adult patients. Data can also be filtered by type of drug, as the limiting appropriate for one drug may not be appropriate for another drug (or even for the same drug of a different concentration). Filters can therefore present the appropriate data sets so that informed decisions can be made to ensure the safety of patients being treated on pumps coupled to the system. Moreover, unlike the static reporting of traditional aggregators, wherein a text document is commonly presented via paper or electronically for board or clinician review, once new or changed limiting values are selected, the values can be automatically programmed to operably coupled pumps.


In another feature and advantage of various embodiments, an aggregating server is configured to calculate when a statistically significant number of data points has been obtained by one or more data gathering pumps. According to the understanding of one skilled in the art, a particular sample size is required in order to make inferences about a particular data population from a sample. Therefore, the aggregating server can automatically calculate the statistically significant number of data points required of any particular data population or data set, filtered or unfiltered. In other embodiments, the data manipulation described herein can also be performed on non-statistically significant sets of data.


In another feature and advantage of various embodiments, the aggregating server can be integrated with other statistically integrated tools and strategies for process improvement, such as Continuous Quality Improvement (CQI), Six Sigma, or Lean Processing, as well as any other suitable improvement process. In an embodiment, for example, any infusion outside of a LSL or USL can be logged as a CQI event. A review board, clinician, or other user can then review and adjust limiting based on the collected data and/or logged events to drive better practice. In other embodiments, the recorded CQI event is used to facilitate training of other clinicians or practitioners involved in the operation of the pumps.


The aforementioned aggregation and automated data analysis and manipulation therefore offers embodiments that reduce the amount of time required to establish drug profiles and limits around those profiles. For example, the manipulation of limits or capability indices in the aforementioned examples is much faster than hand-entering a drug, a drug concentration, the patient weight, and hand-calculating limit boundaries. Time and money is therefore saved by hospitals, clinicians, and administrators implementing embodiments of subject matter hereof.


In an embodiment, a method of establishing a smart pump through pump mode transition includes initial operation as a “Rate, Volume, Run” pump, intermediate operation as a data gathering pump, and final operation as a smart pump with drug library interaction. In embodiments, a transition plan aids practitioner training on, and implementation of, smart pumps and drug libraries. For example, a health care facility can have simple “Rate, Volume, Run” pumps, but desire to transition to smart pumps. According to embodiments, emulation of “Rate, Volume, Run” pumps by smart pumps enables practitioners in the facility to become accustomed to the physical designs, layouts, displays, user interfaces and input means, and ergonomics, etc., of the smart pumps before attempting to utilize or interact with advanced smart pump functionality.


In addition to emulation of “Rate, Volume, Run” pumps by smart pumps, data gathered can be analyzed to look for care area or practitioner irregularities or departures from best practices. That is, the smart pumps can employ or provide various data comparison schemes to identify beneficial or detrimental trends or practices in delivery of medication to patients. Also, based on a particular total data set within a hospital, an aggregating server can, for example, show practitioners how many different drug programs or profiles are needed to optimize specific patient population dosing ranges. As such, potentially detrimental “overlap” can be minimized or perhaps even eliminated. For example, one program or profile can be optimized for a neonatal intensive care unit and another program or profile can be optimized for an operating room or surgical suite, etc. Furthermore, “scenario analysis” can thus be optimized, allowing the software to recognize that a particular patient does not belong in a profile that may have been erroneously selected.


The above summary is not intended to describe each illustrated embodiment or every implementation of the subject matter hereof. The figures and the detailed description that follow more particularly exemplify these embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying figures, in which:



FIG. 1 is a block diagram of a system for the creation and maintenance of a drug library for the safe delivery of medication, according to an embodiment.



FIG. 2 is a block diagram of a system for the creation and maintenance of a drug library for the safe delivery of medication, according to an embodiment.



FIG. 3 is a flow diagram of a method of creating a drug library, according to an embodiment.



FIG. 4 is an illustration of an example of information that can be required when building a drug library, according to an embodiment.



FIG. 5 is an illustration of an example of implementation of a method of building a drug library with upper hard and soft limits, and lower hard and soft limits, according to an embodiment.



FIG. 6 is an illustration of the example of FIG. 5, wherein new lower and upper soft limits have been set, according to an embodiment.



FIG. 7 is an illustration of the example of FIG. 4, additionally showing compliance for each drug in the library, according to an embodiment.



FIG. 8 is an illustration of an example of a timeline of infusions for a particular patient for evaluation of compliance with the drug library, according to an embodiment.



FIG. 9 is a flow diagram of a method of pump transition, according to an embodiment.



FIG. 10 is a flow diagram of a system for the creation and maintenance of a drug library, according to an embodiment.





While embodiments are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to be limited to or by the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the subject matter hereof as defined by the appended claims.


DETAILED DESCRIPTION OF THE DRAWINGS

Devices and methods described in greater detail by way of examples herein provide for the scaling and building of drug libraries and medication safety software by way of graphical user interfaces. The devices and methods also provide valuable information on infusions performed in compliance with medication safety parameters, along with automatic or manual updating of drug libraries and a capability of selecting a particular drug in the library and viewing its delivery history and compliance data. The devices and methods further provide for the intuitive and relatively easy transitions from use of basic infusion pumps to smart pump functions. These features and functions are described by example in the following descriptions, with reference to the drawings.


Referring to FIG. 1, a system 100 for the creation and maintenance of a drug library for the safe delivery of medication generally comprises aggregating server 102 and one or more pumps 104 operably coupled to aggregating server 102. In an embodiment, aggregating server 102 comprises one or more drug lists 106, an aggregator 108, and a user interface 110.


According to an embodiment of aggregating server 102, a drug list 106 comprises a particular drug name, one or more delivery concentrations, and one or more dose rates for a particular drug. In embodiments, one or more drug lists 106 can comprise a separate list for each unique drug, or a concatenated list for all drugs.


Aggregator 108, in an embodiment, comprises an interface for one or more pumps 104 and storage for data received from the one or more pumps 104. In embodiments, aggregator 108 is configured to receive infusion data from pumps 104. Infusion data can comprise any data related to the infusion(s) performed by the transmitting pump. Referring to FIG. 4, examples of infusion data include the drug name, the pump location, the medication amount, the medication units, the diluent amount, the diluent units, the medication maximum rate, the dose rate dosing unit, dose timing, and limiting data. Infusion data can further comprise other general data about the patient with respect to the infusion, such as patient weight, patient age, patient gender, or other patient characteristics, such as patient risk characteristics. Aggregator 108 is further configured to store the infusion data, either in raw form or a synthesized form, for example, in the coupled storage of aggregating server 102, as will be discussed in reference to FIG. 2.


Generally, as will be discussed in further detail below, one or more pumps 104 send infusion data to aggregating server 102. In particular, aggregator 108 acts as a receiver for the transmitted infusion data. Aggregator 108 then interfaces with drug list 106 to combine or otherwise synthesize the particular drug list with the transmitted infusion data, where applicable. For example, the drug list 106 for HEParin will be integrated by aggregator 108 with transmitted infusion data related to HEParin. This data can then be interfaced to user interface 110 for further manipulation or analysis by a user of aggregating server 102. In general, as will be referred to herein, the combination of a drug list 106 and data from one or more pumps 104 creates a “drug library.”


User interface 110 generally comprises a graphical user interface or other appropriate electronic display for viewing, analyzing, and modifying the synthesized drug library. For example, user interface 110 can be viewable on a computer monitor operably coupled to aggregating server 102. In embodiments, user interface 110 can be integrated into a tablet, smartphone, PDA, or other suitable device. Examples of user interactions with user interface 110 are discussed herein.


Pumps 104 each comprise, for example, a syringe pump to controllably force fluid outwardly therefrom to a patient. Further, an embodiment of pump 104 can comprise a processor and memory, while another embodiment of pump 104 can be in communication with another device which provides such processor and memory functions for interaction of pump 104 with aggregating server 102. In embodiments, pumps are used to control delivery to a patient of medications or fluids that include, but are not limited to: therapeutic agents; nutrients; drugs; medicaments such as antibiotics, blood clotting agents, and analgesics; and other fluids. The devices can be used to introduce the medications or fluids into the body of a patient utilizing any of several routes such as, for example, intravenously, subcutaneously, arterially, or epidurally. Each of pumps 104 comprises a communication interface to aggregating server 102. The communication interface can comprise any number of suitable protocols, and can be wired or wireless, in embodiments. Each of pumps 104 can interface directly to aggregator 108, other components of aggregating server 102.


Referring to FIG. 2, the one or more drug lists 106, aggregator 108, and user interface 110 can be implemented via aggregating server 102 as shown with processor 112, memory 114, and bus 116 in system 200.


Processor 112 can be any programmable device that accepts digital data as input, is configured to process the input according to instructions or algorithms, and provides results as outputs. In an embodiment, processor 112 can be a central processing unit (CPU) configured to carry out the instructions of a computer program. Processor 112 is therefore configured to perform basic arithmetical, logical, and input/output operations.


Memory 114 can comprise volatile or non-volatile memory as required by the coupled processor 112 to not only provide space to execute the instructions or algorithms, but to provide the space to store the instructions themselves. In embodiments, volatile memory can include random access memory (RAM), dynamic random access memory (DRAM), or static random access memory (SRAM), for example. In embodiments, non-volatile memory can include read-only memory, flash memory, ferroelectric RAM, hard disk, floppy disk, magnetic tape, or optical disc storage, for example. The foregoing lists in no way limit the type of memory that can be used, as these embodiments are given only by way of example and are not intended to limit the scope of the subject matter hereof.


Bus 116 comprises one or more subsystems for data transfer between processor 112 and memory 114. As such, bus 116, in an embodiment, is operably coupled to processor 112 and memory 114.


Moreover, referring again to FIG. 2, system 200 is further illustrated with Hospital Information System (HIS) 118 and interfacing device 120.


HIS 118 comprises the information or management system of a hospital, with all of its subcomponents and subsystems. HIS 118 can be configured to transmit data to aggregating server 102 for integration, by aggregator 108, into the drug libraries. Likewise, data can be transmitted from aggregating server 102 to HIS 118 for informational, reporting, or patient care purposes. Such data can be any kind of infusion or patient data as described above.


As shown in FIG. 2, interfacing device 120 is a laptop computer, but can also include a tablet, smartphone, PDA, or other suitable device as discussed above with respect to the integration of user interface 110.


As shown, HIS 118 and interfacing device 120 are operably coupled to aggregating server 102. Such coupling can be implemented by any suitable network protocol, including cellular-type networks such as GSM network protocols, UMTS network protocols, CDMA network protocols and the like or other wireless network protocols such IEEE 802.11 or Wi-Fi, IEEE 802.16 or WiMAX and the like. In embodiments, the coupling is via wired networks, such as Ethernet standards IEEE 802.3. In embodiments, interfacing device 120 can be utilized to build and manage a drug library by access of and interface with the aggregation and synthesizing of aggregator 108 and drug lists 106, in combination with input from HIS 118, where applicable.


Although not illustrated, in another embodiment, HIS 118 can comprise a plurality of HIS platforms or “data warehouses” that contain patient treatment information, etc. Additionally, various treatment and dosing schemes can be advantageously employed through gathering, selecting, and characterizing such patient data as described in, for example, U.S. Pat. No. 6,132,416 and U.S. Patent Application Pub. Nos. 2006/0000480, 2006/0137696, 2010/0057488, and 2011/0264462, each of which is incorporated herein by reference in its entirety.


In embodiments, referring to FIG. 3, a method of building a drug library 300 is illustrated. At 302, a drug list is received; for example, drug list 106. In embodiments, drug list 106 can be provided by, for example, HIS 118 or interfacing device 120, or user interface 110. In embodiments, drug list 106 can be hand-entered or batch downloaded. At 304, aggregating server 102 receives infusion and/or operational data from one or more pumps 104. In embodiments, aggregator 108 receives the infusion and/or operational data. The data can be stored in memory 114 by operation of processor 112 and bus 116. At 306, aggregator 108, in combination with drug lists 106, as described, aggregates and synthesizes the drug lists and received infusion data from pumps 104. As such, a drug library is created. The drug library can then be stored in memory 114 by operation of processor 112 and bus 116, or can be dynamically created by future synthesis of aggregator 108. The drug library can then be implemented on any pumps 104 or other medical devices utilizing similar data. In embodiments, the data gathering of pumps 104 and the implementation of the drug library are on the same pumps. In other embodiments, the data gathering of pumps 104 and the implementation of the drug library are on different pumps.



FIG. 4 illustrates an example of some information that can be used in building a drug library, including LHLs, LSLs, USLs, UHLs. Building a drug library often requires substantial research and data entry time prior to implementation of a pump utilizing such safety information. In contrast, a simple drug list, as mentioned above; for example, drug list 106 can contain relatively less information such as drug names, concentrations, and dose rates, according to an embodiment. For example, a drug list, when combined with a pump that is configured to be a “data gathering” pump, allows clinical personnel to build drug libraries based on current practices.



FIG. 5 illustrates an example of implementation of a method of building a drug library with upper hard and soft limits, and lower hard and soft limits, by way of a graphical user interface or other applicable electronic display and input device (collectively, as referenced throughout this document, “GUI”), such as user interface 110. In a right side inset in FIG. 5, an example of a GUI screen-shot bar chart titled “Dose History for HEParin” is shown. Referring to dashed vertical lines in leftmost and rightmost portions of this bar chart, it is visually apparent that the charted infusions are within the set LSL and USL. In an event that a practitioner would desire to further restrict administration of this drug, the LSL and USL bars could, for example, be “grabbed” and “dragged” on the GUI in touch-screen fashion to such new positions on the GUI as shown in FIG. 6, according to an embodiment. Examples of touch screen devices generally are disclosed in U.S. Patent Application Pub. Nos. 2006/0097991 titled “Multipoint Touchscreen” and in 2011/0193788 titled “Graphical Objects that Respond to Touch or Motion Input,” which are incorporated herein by reference in their entireties. Examples of novel and inventive infusion pump technologies employing touch screen devices are disclosed in U.S. Pat. No. 5,485,408 titled “Pump Simulation Apparatus” and in U.S. Patent Application Pub. No. 2009/0270810 titled “Security Features for a Medical Infusion Pump,” which are incorporated herein by reference in their entireties. In other embodiments, other graphical user interface or non-graphical user interface implementations for updating upper hard and soft limits and lower hard and soft limits are considered, such as through the use of slider bars, text boxes, radio buttons, keyed entry, or any other suitable interface embodiments.


The GUI and its associated hardware and software, for example, referring to FIGS. 1-2 and aggregating server 102 and pumps 104, in embodiments, can then be configured and provided to responsively re-analyze the data, and display on the chart how the infusions charted in FIG. 5 would have compared to the new LSL and USL as charted in FIG. 6. In this example, the new LSL would result in 99.67% compliance and the new USL would result in 96.84% compliance, with a total of 3.49% of all HEParin infusions falling outside the soft limits based on these settings. Upon completion of the analysis the new soft limits can be automatically or manually input to the drug library and uploaded to associated infusion pumps via, for example, a wired or wireless connection as operably coupled as discussed above. It is to be particularly appreciated and understood that adjusting infusion limits in such a manner results in a relatively fast and intuitive representation of the infusion data. This in turn allows a drug library administrator to quickly and easily analyze and change limits based on current best or desired practices.


Additionally, a compliance target can be assigned as a default, in an embodiment. For example, when building the drug library, the default value for compliance could be set to 98%. Based on this default value, the LSL and USL is suggested by the software.


Further, with reference to FIG. 7, compliance of the drug library can be intuitively displayed as shown in the rightmost column of the chart, with compliance being listed for each drug in the drug library. In embodiments, the compliance value or compliance percentage can be highlighted in red, green, or any other color or highlighting scheme to indicate the relative conformity to the particular USL and LSL. For example, a compliance value of 98.2% can be colored green, while a compliance value of 85.0% can be colored red, in order to better highlight to the user the compliance of each particular drug in the drug library. As such, for example, a summary of drug settings would be provided along with compliance data for particular infusions as compared to the settings. For further details, a user could “click on,” “touch on,” or otherwise select a particular drug in the library, with delivery history and compliance data for that particular drug (such as shown, for example, in FIG. 6) then being responsively communicated to and displayed on the GUI.


Referring to FIG. 7, information on basic or simple “Rate, Volume, Run” infusions as aforementioned can also be contained within the drug library (for example, in the bottom row of FIG. 7). In embodiments, the bottom row can be highlighted with coloring or other markings to indicate “Rate, Volume, Run” infusions from infusions utilizing limits and/or compliance with a drug library. The goal of a health care facility using such a medication safety device and method may be 100% compliance (i.e., zero basic infusions) for ensuring patient safety. By having both compliance and non-compliance (i.e., basic) infusion data presented together, practitioners and drug library administrators can effectively and easily monitor overall compliance with infusion safety limits.


Referring now to FIG. 8, an example of a GUI timeline of infusions for a particular patient, for evaluation of compliance with the drug library is illustrated. In some cases, such as in emergency or time-critical situations, practitioners must deliver medications outside normal or otherwise acceptable parameters—such as when, for example, a patient is in imminent danger without administration of a particular life-saving medication. In such situations, practitioners typically will resort to administration of basic “Rate, Volume, Run” infusions or even rapid, manual injections of bolus doses. As shown in the example of FIG. 8, the GUI can display such events as a “pump history” log, thereby increasing awareness of potential occurrences of non-compliance with drug library safety limits. In embodiments, “Rate, Volume, Run” infusions can be highlighted in red, green, or any other color or highlighting scheme to easily allow the user to differentiate those infusions from infusions utilizing limits and/or compliance with a drug library. In this example, pump events are plotted on a timeline: a HEParin infusion was started at 8:17 on Dec. 13, 2011; at 11:38 the same pump was started in a basic infusion mode; at 14:21 it was changed back to a HEParin infusion; and at 18:50 the rate was adjusted to 700 units/hr.


Regardless of a particular embodiment of subject matter hereof, it is to be particularly appreciated and understood that medication safety devices and methods—which have been described by example or otherwise contemplated herein—provide data visualization tools that are easy to use and that facilitate scaling and building of medication safety software and drug libraries, etc. It is also to be particularly appreciated and understood that such information can be efficiently and easily derived from current clinical practice data as aforedescribed.


In an embodiment, medication safety devices and methods can be configured to provide an intuitive transition from “Rate, Volume, Run” pumps to smart pumps. The configuration of the pump, whether a simple “Rate, Volume, Run” pump, data gathering pump, or smart pump, could be controlled by a health care facility to enhance patient protection while making administration of drug libraries and safety limits easier and more efficient.


For example, referring to FIG. 9, a method of pump transition 400 comprises initial operation as a “Rate, Volume, Run” pump 402, an intermediate operation as a data gathering pump 404, and final operation as a smart pump 406 with drug library interaction.


In some instances, a transition plan can be of assistance for practitioner training on, and implementation of, smart pumps and drug libraries. For example, a health care facility can have simple “Rate, Volume, Run” pumps, but desire to transition to smart pumps. Referring to operation as a “Rate, Volume, Run” pump 402, embodiments can provide emulation of “Rate, Volume, Run” pumps by smart pumps. Such a feature allows practitioners in the facility to become accustomed to the physical designs, layouts, displays, user interfaces and input means, and ergonomics, etc., of the smart pumps before attempting to utilize or interact with advanced smart pump functionality. After a desired introductory period has elapsed, the health care facility's infusion pump administrator or manager could then, for example, adjust the pumps' operating parameters to require determination and selection of drugs, drug concentrations from drug lists, and patient weights in transition to smarter pump operations—to allow the practitioners to more easily become accustomed to entering and use of such infusion parameters.


For example, such emulation can be in combination with that of a data gathering pump as in data gathering pump 404 operation, wherein data being gathered is used to build the drug library automatically. In data gathering pump 404 operation, according to an embodiment, intermediate steps within data gathering operation are considered. For example, the data gathering pump 404 can first be implemented with a drug list. Subsequently, the data gathering pump 404 can transmit infusion data related to drugs on the drug list to aggregating server 102 for aggregation by aggregator 108.


As a last step in the transition process from “Rate, Volume, Run” pumps to smart pumps 406, upper and lower hard and soft limits could be employed and compliance could be logged and displayed as aforedescribed. In an embodiment, the smart pump 406 with drug library interaction can include utilizing a pump with a drug library downloaded to the pump, for example, on pumps 104, or by interfacing to the drug library stored on memory 114 of aggregating server 102.


It is to be appreciated and understood that, however, a particular facility could choose to implement any desired transition scheme such as, for example, immediately moving from “Rate, Volume, Run” pumps to smart pumps without the intermediate emulation of data gathering pumps; or emulations could be done in any order with any selected individual or groups of functions. Moreover, the particular mode can be selected among any of the operation as a “Rate, Volume, Run” pump 302, intermediate operation as a data gathering pump 304, or final operation as a smart pump 306 with drug library interaction.


Irrespective of a particular embodiment, it is to be appreciated and understood that medication safety devices and methods—as disclosed by example or otherwise contemplated herein—can be characterized in that intuitive visualization is employed for adjusting parameters of a drug library such as soft limits. Furthermore, the devices and methods can be characterized in that a transition from use of a basic infusion pump to a smart pump can be made by practitioners without a large amount of work for the creation of a drug library or without uncertainty or a lack of efficiency that often accompanies implementation of new devices and methods.


Referring to FIG. 10, a flow diagram of a system for the creation and maintenance of a drug library, according to an embodiment of the subject matter hereof is illustrated. For diagram context, in most basic Rate-Volume-Run operation, for example, that of Rate-Volume-Run pump 402 in FIG. 9, a method is provided by steps 502 and 504, where the rate and volume are set at 502, and the pump is run at 504. In this example of embodiments of a Rate-Volume-Run pump 402, at 506a, a check is conducted to determine whether a drug list is enabled, in combination with user workflow, as depicted. In the Rate-Volume-Run operation, a drug list is not enabled, and operation therefore proceeds to the pump being run at 504.


In embodiments of a data gathering pump, for example, that of data gathering pump 404, data can be gathered for aggregation by aggregating server 102 by interaction with aspects of the pump. At 506a, if a drug list is enabled, a drug name is selected from the drug list at 508a. Subsequently, that data is transmitted by the pump device to aggregating server 102.


At 506b, a check is conducted to determine whether a concentration is enabled. If a concentration is not enabled, the operation again proceeds to the pump being run at 504. However, if a concentration is enabled, a drug concentration is selected from the drug list at 508b. Subsequently, that data is transmitted by the pump device to aggregating server 102.


At 506c, a check is conducted to determine whether patient parameters are enabled; for example, a weight-based infusion. If operation with patient parameters is not enabled, the operation again proceeds to the pump being run at 504. However, if operation with patient parameters is enabled, a patient weight is entered at 508c. Subsequently, that data is transmitted by the pump device to aggregating server 102.


At 506d, a check is conducted to determine whether age-based patient parameters are enabled. If operation with a patient's age is not enabled, the operation again proceeds to the pump being run at 504. However, if operation with a patient's age is enabled, a patient age is entered at 508d. Subsequently, that data is transmitted by the pump device to aggregating server 102.


At 506e, a check is conducted to determine whether gender-based patient parameters are enabled. If operation with a patient's gender is not enabled, the operation again proceeds to the pump being run at 504. However, if operation with a patient's gender is enabled, a patient age is entered at 508e. Subsequently, that data is transmitted by the pump device to aggregating server 102. Data can be transmitted serially to aggregating server 102 immediately after the aforementioned decision points, or in a batch after processing has completed and the pump is running Therefore, embodiments of data gathering pump 404 can comprise any single or combination of the aforementioned checks and data transmissions, as well as any other suitable data gathering.


Referring, in an embodiment, to smart pump 406 operation, aggregating server 102 is configured to compute drug usage, drug usage by concentration, drug dosing, drug dosing with age, and/or drug dosing with age and gender, or any other appropriate drug or patient data synthesis. In an embodiment, the raw or aggregated data can be flowed back to the pumps from aggregating server 102, as illustrated by the internal data line.


In an embodiment, referring to 510, the aggregated data can be displayed and analyzed by aggregating server 102 in combination with user interface 110, as discussed in FIGS. 4-7, to improve the delivery of medication. As described, embodiments include the updating of limits and content of the drug library. At 512, a check can be conducted by aggregating server 102 or by flags on, for example, pumps 104, to determine if updated drug libraries are desired. In an embodiment, drug library updates can then be transmitted to the pumps at 514.


As described above, HIS 118 can be integrated into the data analysis of aggregating server 102, for example, as illustrated in FIG. 10. For example, when transmitting updates at 514 to the pumps 104, HIS 118 can likewise be updated. Similarly, HIS 118 can transmit data to aggregating server 102 for the inclusion of that data in the drug library analysis.


Regardless of particular components or modes of action, it is to be appreciated and understood that medication safety devices and methods—such as have been described by example or otherwise contemplated herein—can advantageously enhance accuracy, and thus safety and efficacy, in drug delivery to patients.


While medication safety devices and methods have been particularly shown and described with reference to the accompanying figures and specification, it should be understood however that other modifications thereto are of course possible; and all of them are intended to be within the true spirit and scope of novel and inventive devices and methods described herein. Thus, configurations and designs of various features can be modified or altered depending upon particular embodiments. For example, sequencing of various method steps described by example or otherwise contemplated herein can be re-ordered as may be desired in a particular embodiment.


Although subject matter hereof has been described in a context of “syringe pumps”, it is to be appreciated and understood that the subject matter may also be applicable to virtually any infusion delivery device such as, for example, so-called “large volume” pumps and “ambulatory” pumps among others.


It is also to be understood that dimensioning and scaling of the drawings herein have been chosen to clearly show details of example embodiments. Thus, in some embodiments it is possible that spacing between, or orientations of, various features might be variable and visually different from those illustrated. In any event, dimensioning and scaling can vary significantly across various embodiments of medication safety devices and methods.


It is also to be understood in general that any suitable alternatives may be employed to provide novel and inventive medication safety devices and methods as described by example or otherwise contemplated herein.


Accordingly, these and other various changes or modifications in form and detail may also be made, without departing from the true spirit and scope of medication safety devices and methods that may be defined by the appended claims.


Persons of ordinary skill in the relevant arts will recognize that the subject matter hereof may comprise fewer features than illustrated in any individual embodiment described above. The embodiments described herein are not meant to be an exhaustive presentation of the ways in which the various features of the subject matter hereof may be combined. Accordingly, the embodiments are not mutually exclusive combinations of features; rather, the subject matter hereof may comprise a combination of different individual features selected from different individual embodiments, as understood by persons of ordinary skill in the art.


Any incorporation by reference of documents above is limited such that no subject matter is incorporated that is contrary to the explicit disclosure herein. Any incorporation by reference of documents above is further limited such that no claims included in the documents are incorporated by reference herein. Any incorporation by reference of documents above is yet further limited such that any definitions provided in the documents are not incorporated by reference herein unless expressly included herein.

Claims
  • 1. A method for operating an infusion pump in accordance with a drug library, including at least one data gathering infusion pump in communication with an aggregating server configured to enable the creation of the drug library, the drug library comprising a list of medications at predefined or standard concentrations, the method of operating the infusion pump including the dynamic updating of the drug library based on current best practices, the method comprising: receiving a drug list via the aggregating server, the drug list including a plurality of listed drug names, one or more delivery concentrations for each of the listed drugs, and one or more dose rates for each of the listed drugs;receiving operational data via the aggregating server from the at least one data gathering infusion pump, the operational data including information related to an actual infusion by the at least one data gathering infusion pump of at least one of the plurality of listed drugs;integrating the drug list and the operational data to create the drug library;automatically updating the drug library with revised upper and lower soft limits to establish a compliance target value to ensure that at least 98% of the received operational data falls within the revised upper and lower soft limits as an aid in promoting compliance with desired patient safety practices; andproviding feedback to the at least one data gathering infusion pump by implementing the drug library including the revised upper and lower soft limits on the infusion pump for operation of the infusion pump pursuant to the drug library.
  • 2. The method of claim 1, wherein the operational data comprises at least one of a rate parameter, a duration parameter, or a volume parameter for the infusion.
  • 3. The method of claim 1, wherein the operational data is at least one of a drug name, an infusion pump location, a medication amount, a medication unit, a diluent amount, a diluent unit, a medication maximum rate, a dose rate dosing unit, a dose timing, a limiting amount, a patient weight, a patient age, a patient gender, or a patient risk characteristic.
  • 4. The method of claim 1, wherein the drug list is received from at least one of a hospital information system, a computer, or by manual entry.
  • 5. The method of claim 1, wherein integrating the drug list and the operational data comprises limiting at least one of the one or more delivery concentrations for one of the listed drugs, one or more dose rates for one of the listed drugs, or a dose amount for one of the listed drugs according to the operational data.
  • 6. The method of claim 1, further comprising logging any received infusion data that falls outside of the revised upper and lower soft limits as a continuous quality improvement event.
  • 7. The method of claim 1, further comprising enabling user modification of the revised upper and lower soft limits to evaluate the effect of a change in the modified upper and lower soft limits on the percentage of the received operational data falls that falls within the modified upper and lower soft limits.
  • 8. The method of claim 1, further comprising optimizing specific patient population dosing ranges by identifying detrimental trends in the received infusion data for the specific patient population.
  • 9. A medication safety system configured to operate an infusion pump in accordance with a dynamically updated drug library, the medication safety system comprising: at least one data gathering infusion pump adapted to controllably force fluid outwardly therefrom to a patient; andan aggregating server operably coupled to the at least one infusion pump, the aggregating server comprising a processor and memory and configured to: receive a drug list, the drug list including a plurality of listed drug names, one or more delivery concentrations for each of the listed drugs, and one or more dose rates for each of the listed drugs,receive operational data from the at least one data gathering infusion pump, the operational data including information related to an actual infusion by the at least one data gathering infusion pump of at least one of the plurality of listed drugs, andintegrate the drug list and the operational data to create a drug library;automatically updating the drug library with revised upper and lower soft limits to establish a compliance target value to ensure that at least 98% of the received operational data falls within the determined revised upper and lower soft limits as an aid in promoting compliance with desired patient safety practices; andprovide feedback to the at least one data gathering infusion pump by uploading the drug library including the revised upper and lower soft limits to the at least one data gathering infusion pump for implementation.
  • 10. The medication safety system of claim 9, further comprising a hospital information system operably coupled to the aggregating server, wherein the drug list is received by the aggregating server from the hospital information system.
  • 11. The medication safety system of claim 10, further comprising a data network, wherein the hospital information system is operably coupled to the aggregating server via the data network.
  • 12. The medication safety system of claim 9, further comprising an interfacing device configured to update at least one of the drug list, the operational data, or the drug library.
  • 13. The medication safety system of claim 12, wherein the interfacing device is further configured to transmit the drug list to the aggregating server.
  • 14. The medication safety system of claim 12, further comprising a data network, wherein the interfacing device is operably coupled to the aggregating server via the data network.
  • 15. A method of transitioning a data gathering infusion pump, the method comprising: operating the data gathering infusion pump in a rate-volume-run mode;operating the data gathering infusion pump in a data-gathering mode to gather operational data including information related to an actual infusion by the data gathering infusion pump;integrating the gathered operational data with a drug list to create a drug library;automatically updating the drug library with revised upper and lower soft limits to establish a compliance target value to ensure that at least 98% of the received operational data falls within the revised upper and lower soft limits;providing feedback to the data gathering infusion pump by uploading the drug library including the revised upper and lower soft limits integrated operational data from the data gathering infusion pump to the data gathering infusion pump; andoperating the data gathering infusion pump in accordance with the drug library.
  • 16. The method of transitioning a data gathering infusion pump of claim 15, wherein operating the infusion pump in a rate-volume-run mode comprises emulating a rate-volume-run pump by receiving a rate, receiving a volume, and operating the infusion pump based on the rate and the volume.
  • 17. The method of transitioning a data gathering infusion pump of claim 15, wherein operating the infusion pump in a data-gathering mode comprises recording one or more operational parameters of the rate-volume-run mode.
  • 18. The method of transitioning a data gathering infusion pump of claim 15, wherein operating the infusion pump in a smart-pump mode comprises operating the infusion pump with a drug library.
  • 19. The method of transitioning a data gathering infusion pump of claim 18, wherein the drug library is at least partially created based on one or more operational parameters recorded in the data-gathering mode.
  • 20. A data gathering infusion pump comprising: a pumping mechanism; anda processor configured to operate the data gathering infusion pump in a rate-volume-run mode, operate the data gathering infusion pump in a data-gathering mode to gather operational data including information related to an actual infusion by the data gathering infusion pump, integrate the gathered operational data with a drug list to create a drug library, update the drug library with revised upper and lower soft limits to establish a compliance target value to ensure that at least 98% of the received operational data falls within the revised upper and lower soft limits, provide feedback to the data gathering infusion pump by uploading the drug library including the revised upper and lower soft limits to the infusion pump, and operate the infusion pump in accordance with the drug library.
RELATED APPLICATIONS

This application is a continuation of application Ser. No. 14/763,985 filed Jul. 28, 2015, which is a National Phase entry of PCT Application No. PCT/US2014/012757, filed Jan. 23, 2014, which claims the benefit of U.S. Patent Application No. 61/757,587 entitled “MEDICATION SAFETY DEVICES AND METHODS” and filed Jan. 28, 2013, and U.S. Patent Application No. 61/826,253 entitled “MEDICATION SAFETY DEVICES AND METHODS” and filed May 22, 2013, each of which are incorporated herein by reference in their entireties.

US Referenced Citations (601)
Number Name Date Kind
2968804 Buffington Jan 1961 A
3555286 Cote Jan 1971 A
3603152 Alibert et al. Sep 1971 A
3734229 Comer May 1973 A
3777165 Bryant et al. Dec 1973 A
3809871 Howard et al. May 1974 A
3923060 Ellinwood, Jr. Dec 1975 A
3942526 Wilder et al. Mar 1976 A
3985133 Jenkins et al. Oct 1976 A
4027536 Heggie Jun 1977 A
T961004 Horton Aug 1977 I4
4080967 O'Leary Mar 1978 A
4091550 Schrenk et al. May 1978 A
4098267 Stein et al. Jul 1978 A
4137913 Georgi Feb 1979 A
4141252 Lodge Feb 1979 A
4146029 Ellinwood, Jr. Mar 1979 A
4174637 Mulzet et al. Nov 1979 A
4184815 Casson et al. Jan 1980 A
4191184 Carlisle Mar 1980 A
4210138 Jess et al. Jul 1980 A
4213454 Shim Jul 1980 A
4217993 Jess et al. Aug 1980 A
4236880 Archibald Dec 1980 A
4270532 Frametzki et al. Jun 1981 A
4279188 Scott Jul 1981 A
4280136 Kasbima et al. Jul 1981 A
4282872 Franetzki et al. Aug 1981 A
4299218 Knigge et al. Nov 1981 A
4299541 Ohara et al. Nov 1981 A
4308866 Jelliffe et al. Jan 1982 A
4309993 Brown Jan 1982 A
4311377 Matteson Jan 1982 A
4314227 Eventoff Feb 1982 A
4314228 Eventoff Feb 1982 A
4315238 Eventoff Feb 1982 A
4320757 Whitney et al. Mar 1982 A
4368645 Glenn et al. Jan 1983 A
4369780 Sakai Jan 1983 A
4370983 Lichtenstein Feb 1983 A
4373525 Kobayashi Feb 1983 A
4373527 Fischell Feb 1983 A
4385630 Gilcher et al. May 1983 A
4385958 Long May 1983 A
RE31315 Jenkins et al. Jul 1983 E
4392849 Petre et al. Jul 1983 A
4394862 Shim Jul 1983 A
4395259 Prestele et al. Jul 1983 A
4396977 Slater et al. Aug 1983 A
4398542 Cunningham et al. Aug 1983 A
4410322 Archibald Oct 1983 A
4413314 Slater et al. Nov 1983 A
4425661 Moses et al. Jan 1984 A
4431425 Thompson et al. Feb 1984 A
4443218 DeCant, Jr. et al. Apr 1984 A
4446344 Fiedler May 1984 A
4460355 Layman Jul 1984 A
4484479 Eckhardt Nov 1984 A
4489302 Eventoff Dec 1984 A
4490798 Franks et al. Dec 1984 A
4493704 Beard et al. Jan 1985 A
4494950 Fischell Jan 1985 A
4498843 Schneider et al. Feb 1985 A
4512013 Nash et al. Apr 1985 A
4520706 Deforeit Jun 1985 A
4526574 Pekkarinen Jul 1985 A
4529401 Leslie et al. Jul 1985 A
4530696 Bisera et al. Jul 1985 A
4542532 McQuilkin Jul 1985 A
4534756 Nelson Aug 1985 A
4550731 Batina et al. Nov 1985 A
4550748 Nunez Nov 1985 A
4557725 Heyne et al. Dec 1985 A
4559037 Franetzki et al. Dec 1985 A
4559038 Berg et al. Dec 1985 A
4559044 Robinson et al. Dec 1985 A
4561443 Hogrefe Dec 1985 A
4562751 Nason et al. Jan 1986 A
4563179 Sakai Jan 1986 A
4565542 Berg Jan 1986 A
4578573 Flies et al. Mar 1986 A
4596575 Rosenberg et al. Jun 1986 A
4597754 Thill et al. Jul 1986 A
4601702 Hudson Jul 1986 A
4606353 Timm Aug 1986 A
4617014 Cannon et al. Oct 1986 A
4623331 Cewers et al. Nov 1986 A
4624661 Arimond Nov 1986 A
4627835 Fenton, Jr. Dec 1986 A
4627839 Young Dec 1986 A
4649499 Sutton et al. Mar 1987 A
4650469 Berg et al. Mar 1987 A
4652260 Fenton, Jr. Mar 1987 A
4656603 Dunn Apr 1987 A
4658371 Walsh et al. Apr 1987 A
4671792 Borsanyi Jun 1987 A
4676776 Hawson Jun 1987 A
4678408 Nason et al. Jul 1987 A
4681563 Deckert et al. Jul 1987 A
4685903 Cable et al. Aug 1987 A
4690673 Blomquist Sep 1987 A
4692147 Duggan Sep 1987 A
4696671 Epstein et al. Sep 1987 A
4710163 Butterfield Dec 1987 A
4714462 DiDomenico Dec 1987 A
4722734 Kollin Feb 1988 A
D294733 Peterson et al. Mar 1988 S
4731051 Fischell Mar 1988 A
4731058 Doan Mar 1988 A
4731726 Allen, III Mar 1988 A
4739229 Heiler et al. Apr 1988 A
4741732 Granshaw et al. May 1988 A
4745301 Michalchik May 1988 A
4747828 Tseo May 1988 A
4754401 Kaczynski et al. Jun 1988 A
4756706 Kerns et al. Jul 1988 A
4774029 Poulin Sep 1988 A
4775368 Iwatschenko Oct 1988 A
4778449 Weber et al. Oct 1988 A
4785799 Schoon et al. Nov 1988 A
4790816 Sundblom et al. Dec 1988 A
4799381 Tromp Jan 1989 A
4808161 Karmen Feb 1989 A
4808167 Mann et al. Feb 1989 A
4809697 Causey, III et al. Mar 1989 A
4810243 Howson Mar 1989 A
4810992 Eventoff Mar 1989 A
4816019 Karmen Mar 1989 A
4818186 Pastrone et al. Apr 1989 A
4826810 Aoki May 1989 A
4832033 Maher et al. May 1989 A
4836752 Burkett Jun 1989 A
4838856 Mulreany et al. Jun 1989 A
4838857 Strowe et al. Jun 1989 A
4842584 Pastrone Jun 1989 A
4846792 Bobo, Jr. et al. Jul 1989 A
4847764 Halverson Jul 1989 A
4847990 Patrick Jul 1989 A
4850807 Frantz Jul 1989 A
4850972 Schulman et al. Jul 1989 A
4852581 Frank Aug 1989 A
4854324 Hirschman et al. Aug 1989 A
4856339 Williams Aug 1989 A
4857716 Gombrich et al. Aug 1989 A
4863425 Slate et al. Sep 1989 A
4869722 Heyman Sep 1989 A
4871351 Feingold Oct 1989 A
4878896 Garrison et al. Oct 1989 A
4882575 Kawahara et al. Nov 1989 A
4889132 Hutcheson et al. Dec 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
4901221 Kodosky et al. Feb 1990 A
4908017 Howson et al. Mar 1990 A
4914568 Kodosky et al. Apr 1990 A
4918930 Gaudet et al. Apr 1990 A
4919650 Feingold et al. Apr 1990 A
4925444 Orkin et al. May 1990 A
4927411 Pastrone et al. May 1990 A
4933873 Kaufman et al. Jun 1990 A
4942514 Miyagaki et al. Jul 1990 A
4943279 Samiotes et al. Jul 1990 A
4950235 Slate et al. Aug 1990 A
4950244 Fellingham et al. Aug 1990 A
4954818 Naking et al. Sep 1990 A
4957690 Fennern Sep 1990 A
4961533 Teller et al. Oct 1990 A
4970664 Kaiser Nov 1990 A
4976151 Morishita Dec 1990 A
4978335 Arthur Dec 1990 A
4979940 Bobo, Jr. et al. Dec 1990 A
4994035 Mokros Feb 1991 A
4996511 Ohkawa et al. Feb 1991 A
5000739 Kulisz et al. Mar 1991 A
5006997 Reich Apr 1991 A
5009641 Gorton Apr 1991 A
5010473 Jacobs Apr 1991 A
5017059 Davis May 1991 A
5032978 Blomquist Jul 1991 A
5034004 Crankshaw Jul 1991 A
5038800 Oba Aug 1991 A
5041086 Koenig et al. Aug 1991 A
5045069 Imparato Sep 1991 A
5047014 Mosebach et al. Sep 1991 A
5050612 Matsumura Sep 1991 A
5053585 Yaniger Oct 1991 A
5053990 Kreifels Oct 1991 A
5062774 Kramer et al. Nov 1991 A
5069668 Boydman Dec 1991 A
5074756 Davis Dec 1991 A
5078682 Miki et al. Jan 1992 A
5078683 Sancoff et al. Jan 1992 A
5082014 Olichney Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5087245 Doan Feb 1992 A
5088983 Burke Feb 1992 A
5096385 Georgi et al. Mar 1992 A
5098262 Wecker et al. Mar 1992 A
5098409 Stock Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5103211 Daoud et al. Apr 1992 A
5104374 Bishko et al. Apr 1992 A
5111234 Taniguchi et al. May 1992 A
5115223 Moody May 1992 A
5116312 Blankenship et al. May 1992 A
5122820 Pagano et al. Jun 1992 A
5124744 Ogura et al. Jun 1992 A
5124802 Ito et al. Jun 1992 A
5131816 Brown et al. Jul 1992 A
5140862 Pappalardo Aug 1992 A
5153827 Coutre et al. Oct 1992 A
5154700 Danby Oct 1992 A
5155693 Altmayer et al. Oct 1992 A
5155847 Kirouac et al. Oct 1992 A
5157928 Gaudlet et al. Oct 1992 A
5168441 Onarheim et al. Dec 1992 A
5172698 Stanko Dec 1992 A
5174472 Raque et al. Dec 1992 A
5176004 Gaudet Jan 1993 A
5181910 Scanlon Jan 1993 A
5190442 Jorritsma Mar 1993 A
5190522 Wojiciki et al. Mar 1993 A
5207642 Orkin et al. May 1993 A
5211626 Frank et al. May 1993 A
5213573 Hyman et al. Jun 1993 A
5217355 Hyman et al. Jun 1993 A
5219327 Okada Jun 1993 A
5221268 Barton et al. Jun 1993 A
5224051 Johnson Jun 1993 A
5230623 Guthrie et al. Jul 1993 A
5238001 Gallant et al. Aug 1993 A
5241461 Georges Aug 1993 A
5244461 Derlien Sep 1993 A
5244463 Cordner, Jr. et al. Sep 1993 A
5247434 Peterson et al. Sep 1993 A
5256157 Samiotes et al. Oct 1993 A
5265431 Gaudet et al. Nov 1993 A
5267174 Kaufman Nov 1993 A
5267218 Elbert Nov 1993 A
5291190 Scarola et al. Mar 1994 A
5295062 Fukshima Mar 1994 A
5301301 Kodusky et al. Apr 1994 A
5307262 Ertel Apr 1994 A
5307263 Brown Apr 1994 A
5315530 Gerhardt et al. May 1994 A
5317506 Coutre et al. May 1994 A
5319363 Welch Jun 1994 A
5321601 Riedel et al. Jun 1994 A
5338157 Blomquist Aug 1994 A
5339821 Fujimoto Aug 1994 A
5350411 Ryan et al. Sep 1994 A
5353316 Scarola et al. Oct 1994 A
5354273 Hagen Oct 1994 A
5356378 Doan Oct 1994 A
5357427 Langen et al. Oct 1994 A
5363482 Victor et al. Nov 1994 A
5364346 Schrezenmeir Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5376070 Purvis et al. Dec 1994 A
5378231 Johnson Jan 1995 A
5383855 Nicholson et al. Jan 1995 A
5386360 Wilson et al. Jan 1995 A
5388202 Squires et al. Feb 1995 A
5389071 Kawahara et al. Feb 1995 A
5389078 Zelesky et al. Feb 1995 A
5395321 Kawahara et al. Mar 1995 A
5400246 Wilson et al. Mar 1995 A
5412400 Takahara et al. May 1995 A
5429602 Hauser Jul 1995 A
5431627 Pastrone et al. Jul 1995 A
5432709 Vollweiler et al. Jul 1995 A
5440585 Patridge, III Aug 1995 A
5456691 Snell Oct 1995 A
5478211 Dominiak et al. Dec 1995 A
5479643 Bhaskar et al. Dec 1995 A
5481250 Hano Jan 1996 A
5482446 Williamson et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5531697 Olsen et al. Jul 1996 A
5531698 Olsen Jul 1996 A
5537436 Bottoms et al. Jul 1996 A
5558640 Pfeiler et al. Sep 1996 A
5569187 Kaiser Oct 1996 A
5573506 Vasko Nov 1996 A
5575631 Jester Nov 1996 A
5582593 Hultman Dec 1996 A
5594786 Chaco et al. Jan 1997 A
5598420 Kaufman Jan 1997 A
5616121 McKay Apr 1997 A
5626144 Tacklind et al. May 1997 A
5630710 Tunc et al. May 1997 A
5643212 Coutre et al. Jul 1997 A
5647854 Olsen et al. Jul 1997 A
5658250 Blomquist et al. Aug 1997 A
5658252 Johnson Aug 1997 A
5660176 Iliff Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5681285 Ford Oct 1997 A
5685844 Marttila Nov 1997 A
5687717 Halpern et al. Nov 1997 A
5687734 Dempsey et al. Nov 1997 A
5695473 Olsen Dec 1997 A
5704366 Tacklind et al. Jan 1998 A
5706458 Koppolu Jan 1998 A
5713856 Eggers et al. Feb 1998 A
5717603 McClendon et al. Feb 1998 A
5718562 Lawless et al. Feb 1998 A
5719761 Gatti et al. Feb 1998 A
5729735 Meyering Mar 1998 A
5737539 Edelson et al. Apr 1998 A
5764159 Neftel Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5781442 Engleson et al. Jul 1998 A
5782805 Meinzer et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5807336 Russo et al. Sep 1998 A
5810771 Blomquist Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5833599 Schrier et al. Nov 1998 A
5857967 Frid et al. Jan 1999 A
5861018 Feierbach Jan 1999 A
5868669 Iliff Feb 1999 A
5871465 Vasko Feb 1999 A
5875242 Glaser et al. Feb 1999 A
5876370 Blomquist Mar 1999 A
5879163 Brown et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5895371 Levitas et al. Apr 1999 A
5897493 Brown Apr 1999 A
5899855 Brown May 1999 A
5913310 Brown Jun 1999 A
5918603 Brown Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5933136 Brown Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5940623 Watts et al. Aug 1999 A
5940801 Brown Aug 1999 A
5950190 Yeager et al. Sep 1999 A
5956501 Brown Sep 1999 A
5960403 Brown Sep 1999 A
5966691 Kibre et al. Oct 1999 A
5997476 Brown Dec 1999 A
6012034 Hamparian et al. Jan 2000 A
6024539 Blomquist Feb 2000 A
6032119 Brown et al. Feb 2000 A
6077055 Vilks Jun 2000 A
6101478 Brown Aug 2000 A
RE36871 Epstein et al. Sep 2000 E
6132416 Broselow Oct 2000 A
6164921 Moubayed Dec 2000 A
6219674 Classen Apr 2001 B1
6222482 Gueziec Apr 2001 B1
6241704 Peterson et al. Jun 2001 B1
6246992 Brown Jun 2001 B1
6248067 Mavity et al. Jun 2001 B1
6269340 Ford et al. Jul 2001 B1
6363282 Nichols et al. Mar 2002 B1
6406426 Reuss et al. Jun 2002 B1
6421650 Goetz et al. Jul 2002 B1
6422057 Anderson Jul 2002 B1
6475180 Peterson et al. Nov 2002 B2
6500156 Stansbury Dec 2002 B1
6519569 White Feb 2003 B1
6551276 Mann et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6671563 Engelson et al. Dec 2003 B1
6689091 Bui et al. Feb 2004 B2
6694334 Dulong Feb 2004 B2
6714969 Klein et al. Mar 2004 B1
6744350 Blomquist Jun 2004 B2
6749586 Vasko Jun 2004 B2
6765877 Foschiano et al. Jul 2004 B1
6790198 White et al. Sep 2004 B1
6809653 Mann et al. Oct 2004 B1
6852104 Blomquist Feb 2005 B2
6872200 Mann et al. Mar 2005 B2
6903743 Ng Jun 2005 B2
6904434 Wallach et al. Jun 2005 B1
6936029 Mann et al. Aug 2005 B2
6956572 Zaleski Oct 2005 B2
6979326 Mann et al. Dec 2005 B2
6997920 Mann et al. Feb 2006 B2
6999854 Roth Feb 2006 B2
7018361 Beck et al. Mar 2006 B2
7025743 Mann et al. Apr 2006 B2
7033338 Vilks et al. Apr 2006 B2
7036089 Bauer Apr 2006 B2
7041082 Blomquist et al. May 2006 B2
7042643 Miles May 2006 B2
7098803 Mann et al. Aug 2006 B2
7103578 Beck et al. Sep 2006 B2
7109878 Mann et al. Sep 2006 B2
7233781 Hunter et al. Jun 2007 B2
7300418 Zaleski Nov 2007 B2
7324012 Mann et al. Jan 2008 B2
7347836 Peterson Mar 2008 B2
D570363 Ulm et al. Jun 2008 S
7384410 Eggers et al. Jun 2008 B2
D576175 Onodera Sep 2008 S
D580948 Tomizawa et al. Nov 2008 S
7454314 Holland Nov 2008 B2
D586351 Gelman et al. Feb 2009 S
D586357 Janinski Feb 2009 S
D604741 DeBleser et al. Nov 2009 S
7624029 Ghouri Nov 2009 B1
7647237 Malave et al. Jan 2010 B2
7654976 Peterson et al. Feb 2010 B2
7689939 Becker Mar 2010 B1
7708717 Estes et al. May 2010 B2
7789859 Estes et al. Sep 2010 B2
7794427 Estes et al. Sep 2010 B2
7835927 Schlotterbeck et al. Nov 2010 B2
7895527 Zaleski Feb 2011 B2
7912674 Clark Mar 2011 B2
8020564 Batch Sep 2011 B2
8065161 Howard Nov 2011 B2
8149131 Blomquist Apr 2012 B2
8182461 Pope May 2012 B2
8209060 Ledford Jun 2012 B2
8234128 Martucci et al. Jul 2012 B2
8250483 Blomquist Aug 2012 B2
8313433 Cohen Nov 2012 B2
8346399 Blomquist Jan 2013 B2
8435206 Evans et al. May 2013 B2
8504179 Blomquist Aug 2013 B2
8768717 Blomquist Jul 2014 B2
8858526 Blomquist Oct 2014 B2
8954336 Blomquist Feb 2015 B2
8965707 Blomquist Feb 2015 B2
8974406 Evans et al. Mar 2015 B2
9132230 Blomquist Sep 2015 B2
9135393 Blomquist Sep 2015 B1
9192712 DeBelser et al. Nov 2015 B2
9501949 Hansen et al. Nov 2016 B2
20010031944 Peterson et al. Oct 2001 A1
20010044731 Coffman Nov 2001 A1
20010056259 Skinkle Dec 2001 A1
20020002326 Causey et al. Jan 2002 A1
20020015024 Westerman et al. Feb 2002 A1
20020029776 Blomquist Mar 2002 A1
20020038392 De La Huerga et al. Mar 2002 A1
20020065879 Ambrose et al. May 2002 A1
20020077852 Ford Jun 2002 A1
20020077863 Rutledge Jun 2002 A1
20020091546 Christakis et al. Jul 2002 A1
20020107476 Mann et al. Aug 2002 A1
20020151804 O'Mahony et al. Oct 2002 A1
20020177758 Schoenberg Nov 2002 A1
20020183693 Peterson et al. Dec 2002 A1
20020193679 Malave et al. Dec 2002 A1
20030011646 Levine et al. Jan 2003 A1
20030060765 Campbell et al. Mar 2003 A1
20030069650 Karmiy et al. Apr 2003 A1
20030076792 Theimer et al. Apr 2003 A1
20030114836 Estes et al. Jun 2003 A1
20030139701 White et al. Jul 2003 A1
20030140928 Bui Jul 2003 A1
20030144880 Talachian et al. Jul 2003 A1
20030145053 Bodin Jul 2003 A1
20030163088 Blomquist Aug 2003 A1
20030163223 Blomquist Aug 2003 A1
20030163789 Blomquist Aug 2003 A1
20030173408 Mosher et al. Sep 2003 A1
20030204413 Riff Oct 2003 A1
20030204415 Knowlton Oct 2003 A1
20030204416 Sayeh et al. Oct 2003 A1
20030212364 Mann Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20040010425 Wilkes et al. Jan 2004 A1
20040019607 Moubayed et al. Jan 2004 A1
20040039257 Hickle Feb 2004 A1
20040065321 Stenzler Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040128162 Schlotterbeck et al. Jul 2004 A1
20040162835 Ghouri Aug 2004 A1
20040167465 Mihai et al. Aug 2004 A1
20040167804 Simpson et al. Aug 2004 A1
20040172283 Vanderveen Sep 2004 A1
20040172301 Mihai et al. Sep 2004 A1
20040172302 Martucci et al. Sep 2004 A1
20040176984 White et al. Sep 2004 A1
20040249673 Smith Dec 2004 A1
20050001797 Miller Jan 2005 A1
20050010258 Peterson et al. Jan 2005 A1
20050055242 Bello et al. Mar 2005 A1
20050065817 Mihai et al. Mar 2005 A1
20050102165 Oshita et al. May 2005 A1
20050102167 Kapoor May 2005 A1
20050107923 Vanderveen May 2005 A1
20050119914 Batch Jun 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143864 Blomquist Jun 2005 A1
20050144043 Holland Jun 2005 A1
20050144182 Boris et al. Jun 2005 A1
20050030164 Mann et al. Aug 2005 A1
20050077096 Bollish Aug 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050171815 Vanderveen Aug 2005 A1
20050177096 Bollish Aug 2005 A1
20050177395 Blomquist Aug 2005 A1
20050246416 Blomquist Nov 2005 A1
20060000480 Broselow Jan 2006 A1
20060001550 Mann et al. Jan 2006 A1
20060026205 Butterfield Feb 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060041222 Dewing et al. Feb 2006 A1
20060047538 Condurso et al. Mar 2006 A1
20060079768 Small et al. Apr 2006 A1
20060089539 Miodownik et al. Apr 2006 A1
20060097991 Hotelling May 2006 A1
20060116639 Russell Jun 2006 A1
20060122562 Needle Jun 2006 A1
20060132292 Blomquist Jun 2006 A1
20060137696 Broselow Jun 2006 A1
20060149416 Mohapatra Jul 2006 A1
20060202859 Mastrototaro et al. Sep 2006 A1
20060229557 Fathallah et al. Oct 2006 A1
20060229573 Lamborne Oct 2006 A1
20060247606 Batch Nov 2006 A1
20060258985 Russell Nov 2006 A1
20060264249 Scheer Nov 2006 A1
20070094046 Cobbs et al. Apr 2007 A1
20070098565 Parsee May 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070233520 Wehba Oct 2007 A1
20070255322 Gerber et al. Nov 2007 A1
20070260126 Haumann Nov 2007 A1
20080021396 Momeni Jan 2008 A1
20080030369 Mann et al. Feb 2008 A1
20080033357 Mann et al. Feb 2008 A1
20080033360 Evans et al. Feb 2008 A1
20080033361 Evans et al. Feb 2008 A1
20080033402 Blomquist Feb 2008 A1
20080033749 Blomquist Feb 2008 A1
20080034323 Blomquist Feb 2008 A1
20080065007 Peterson et al. Mar 2008 A1
20080065016 Peterson et al. Mar 2008 A1
20080086331 Hertel Apr 2008 A1
20080091466 Butler Apr 2008 A1
20080103531 Ginggen et al. May 2008 A1
20080126969 Blomquist May 2008 A1
20080132844 Peterson et al. Jun 2008 A1
20080243548 Cafer Oct 2008 A1
20080300534 Blomquist Dec 2008 A1
20080306437 Jacobson et al. Dec 2008 A1
20090058598 Sanchez Sanchez et al. Mar 2009 A1
20090087327 Voltenberg Apr 2009 A1
20090156991 Roberts Jun 2009 A1
20090157695 Roberts Jun 2009 A1
20090165121 Kumar Jun 2009 A1
20090177180 Rubalcaba et al. Jul 2009 A1
20090270810 DeBelser et al. Oct 2009 A1
20090275886 Blomquist et al. Nov 2009 A1
20100020064 Roosendaal et al. Jan 2010 A1
20100057488 Broselow Mar 2010 A1
20100065633 Nelson Mar 2010 A1
20100121654 Portnoy May 2010 A1
20100174229 Hsu et al. Jul 2010 A1
20100228222 Williams Sep 2010 A1
20110004071 Faiola Jan 2011 A1
20110060758 Schlotterbeck et al. Mar 2011 A1
20110145012 Nightingale Jun 2011 A1
20110193788 King Aug 2011 A1
20110259954 Bartz Oct 2011 A1
20110264043 Kotnik Oct 2011 A1
20110264044 Bartz Oct 2011 A1
20110264045 Thompson Oct 2011 A1
20110264462 Broselow Oct 2011 A1
20110282691 Coffman et al. Nov 2011 A1
20110290973 Gesler Dec 2011 A1
20120013625 Blomquist et al. Jan 2012 A1
20120013802 Blomquist et al. Jan 2012 A1
20120065990 Howard Mar 2012 A1
20120131507 Sparandara May 2012 A1
20120172802 Blomquist Jul 2012 A1
20120278099 Kelly Nov 2012 A1
20120323212 Murphy Dec 2012 A1
20130012876 DeBelser et al. Jan 2013 A1
20130012877 DeBelser et al. Jan 2013 A1
20130012878 Blomquist Jan 2013 A1
20130012879 Debelser et al. Jan 2013 A1
20130012880 Blomquist Jan 2013 A1
20130015980 Evans et al. Jan 2013 A1
20130018315 Blomquist Jan 2013 A1
20130042194 Gannon Feb 2013 A1
20130131630 Blomquist May 2013 A1
20140094744 Blomquist Apr 2014 A1
20140094764 Blomquist Apr 2014 A1
20140095485 Blomquist Apr 2014 A1
20140095499 Blomquist Apr 2014 A1
20140195954 Doshi Jul 2014 A1
20150154369 Blomquist Jun 2015 A1
20150161354 Blomquist Jun 2015 A1
20150367065 Adams et al. Dec 2015 A1
20160000994 Blomquist Jan 2016 A1
20160147978 Adams et al. May 2016 A1
Foreign Referenced Citations (87)
Number Date Country
2060151 Aug 1992 CA
2485024 Nov 2003 CA
2511931 Jul 2004 CA
2554903 Apr 2005 CA
2607297 Nov 2006 CA
2647816 Nov 2007 CA
2659494 Feb 2008 CA
665955 Jun 1988 CH
0069350 Jan 1983 EP
0078645 May 1983 EP
0183351 Jun 1986 EP
0188288 Jul 1986 EP
0221005 May 1987 EP
0233115 Aug 1987 EP
319272 Jun 1989 EP
0328162 Aug 1989 EP
0384155 Aug 1990 EP
408483 Jan 1991 EP
0497041 Aug 1992 EP
503670 Sep 1992 EP
0371507 Mar 1993 EP
551088 Jul 1993 EP
0806738 Nov 1997 EP
0952541 Oct 1999 EP
1587017 Oct 2005 EP
1647291 Apr 2006 EP
2603488 Mar 1988 FR
2039083 Jul 1980 GB
2262452 Jun 1993 GB
2312055 Oct 1997 GB
409192218 Jul 1997 JP
10143573 May 1998 JP
2002291706 Oct 2002 JP
2010507176 Mar 2010 JP
10-2010-0126598 Dec 2010 KR
WO8703814 Jul 1987 WO
WO8707161 Dec 1987 WO
WO9116609 Oct 1991 WO
WO9208647 May 1992 WO
WO9215439 Sep 1992 WO
WO9405355 Mar 1994 WO
WO9408647 Apr 1994 WO
WO 8403218 Aug 1994 WO
WO9502426 Jan 1995 WO
WO9525893 Sep 1995 WO
WO9528190 Oct 1995 WO
WO9603168 Feb 1996 WO
WO1996013790 May 1996 WO
WO9620745 Jul 1996 WO
WO9636389 Nov 1996 WO
WO9725083 Jul 1997 WO
WO9715227 Apr 1998 WO
WO9820439 May 1998 WO
WO9824358 Jun 1998 WO
WO9842407 Oct 1998 WO
WO9859487 Dec 1998 WO
WO9908183 Feb 1999 WO
WO9910801 Mar 1999 WO
WO9918532 Apr 1999 WO
WO9922236 May 1999 WO
WO 9935588 Jul 1999 WO
WO9932031 Jul 1999 WO
WO0003344 Jan 2000 WO
WO0018449 Apr 2000 WO
WO0045696 Aug 2000 WO
WO0048112 Aug 2000 WO
WO 0152727 Jul 2001 WO
WO0211049 Feb 2002 WO
WO03053503 Jul 2003 WO
WO03094075 Nov 2003 WO
WO03097123 Nov 2003 WO
WO03097126 Nov 2003 WO
WO 2005056083 Jun 2005 WO
WO 2005083619 Sep 2005 WO
WO2006023636 Mar 2006 WO
WO 2006073400 Jul 2006 WO
WO 2006122322 Nov 2006 WO
WO2007101260 Sep 2007 WO
WO2008019013 Feb 2008 WO
WO2008019014 Feb 2008 WO
WO2008019015 Feb 2008 WO
WO2008016621 Feb 2008 WO
WO2008048587 Apr 2008 WO
WO2008019016 Nov 2008 WO
WO20090135108 Nov 2009 WO
WO 2012093163 Jul 2012 WO
WO 2012166434 Dec 2012 WO
Non-Patent Literature Citations (240)
Entry
Manrique-Rodriguez, “Developing a drug library for smart pumps in a pediatric intensive care unit,” Artificial Intelligence in Medicine 54 (2012) 155-161 (Year: 2012).
International Search Report, Application No. PCT/US2014/012757, dated May 29, 2014, 3 pages.
Institute for Safe Medication Practices, Proceedings from the ISMP Summit on the Use of Smart Infusion Pumps: Guidelines for Safe Implementation and Use, © 2009, 19 pages.
Vanderveen, Tim, A Decade of “Smart” Infusion Pumps, Feb. 27, 2012, 2 pages.
Huang, Zifang, Prediction of Uterine Contractions Using Knowledge-Assisted Sequential Pattern Analysis, IEEE © 2011, 8 pages.
“A Programable Infusion Pump Controller,” 30th Annual Conference on Engineering in Medicine and Biology, Nov. 5-9, 1977 in Los Angeles, California, 11 pages.
“A Programmable Infusion Pump Controller, ” 30th Annual Conference on Engineering in Medicine and Biology, Nov. 5-9, 1977 in Los Angeles, California, 11 pages.
“ally™ Ambulatory Frug Infusion System”, Q-Life Systems Inc., 3 pages, as submitted Jun. 29, 1988 in U.S. Appl. No. 08/868,913.
“IV700 Service Manual.” Valleylab, Inc. Boulder Colorado; Sep. 1988.
“Product Overview, Verifuse Ambulatory Infusion Pump.” Block Medical Inc, dated Sep. 1990, 4 pages.
510 (k) Registration Documents for Registration of K863997 (1986).
510 (k) Registration Documents for Registration of K87022 and K871728 (1987).
A Semi-closed loop computer-assisted insulin infusion system, Donald J. Chisholm, Edward W. Kraegen, David J. Bell and David R. Chipps, The Medical Journal of Australia, Dec. 8/22, 1984. pp. 13-17.
A Semi-Closed Loop Computer-Assisted Insulin Infusion System. Hospital use for Control of Diabetes in Patients, Chisholm DJ, Kraegan EW, Bell DJ, Chipps DR, Med J. Aust. Dec. 8-22, 1984;141(12-13):784-9.
A Simulation Study on a Self-Tuning Portable Controller of Blood Glucose. Brunetti P, Cobelli C, Cruciani P, Fabietti PG, Filippucci F, Santeusanio F, Sarti E. Medical Pathology Institute, Bioengineering Laboratory. University of Perugia, Italy. Int. J. ArtifOrgans. Jan. 1993; 16(1):51-7.
A Standard Microcomputer Linked to a Volume-Controlled Infusion Pump for Patient-Controlled Analgesia Research, Journal of Medical Engineering and Technology, G.W.A. Gillies, G.N.C. Kenny and C.S. McArdle, vol. 10, No. 2, Mar./Apr. 1986. pp. 55-57.
Abbot Laboratories Blue Line System Life Care ® Model 4 Series System brochure, copyright 1990, 16 pages.
Abbot Literature, 37 pages, as submitted Jun. 29, 1988 in U.S. Appl. No. 08/868,913.
Advertisement from HERCO, Are Control Rooms Obsolete? Dated Mar. 1971, 1 page and Mar. 1972, 1 page.
Answer and Counterclaims of Smiths Medical Md. Inc. (Exhibits 1-5); C.A. 03-776, Medtronic Minimed, Inc. v. Deltec Inc., Smiths Group North America, Inc. and Smiths Group Pic. Nov. 17, 2003.
Application for U.S. Appl. No. 11/499,248, filed Aug. 3, 2006, inventor Blomquist.
Application for U.S. Appl. No. 11/499,240, filed Aug. 3, 2006, inventor Blomquist.
Application for U.S. Appl. No. 11/702,925, filed Feb. 5, 2007 inventors Evans et al.
Application for U.S. Appl. No. 13/620,031, filed Sep. 14, 2012 inventor Blomquist.
Application for U.S. Appl. No. 13/619,964, filed Sep. 14, 2012 inventors Evans et al.
Application for U.S. Appl. No. 14/763,985 dated Jul. 28, 2015, inventors Adams et al.
Application for U.S. Appl. No. 14/851,322, filed Sep. 11, 2015 inventor Blomquist.
Article by McMorris et al., “Are Process Control Rooms Obsolete?”, Control Engineering dated Jul. 1971, pp. 42-47.
Australian Examination Report No. 3 for Australian Application No. 2007282068 dated Jun. 4, 2013.
Australian Examination Report No. 3 for Australian Application No. 2007282068 dated Jun. 17, 2013.
Australian Examiner's first report on Australian Application No. 2007282068 dated May 10, 2012.
Australian Office Action for Application No. 2004296794 dated Dec. 3, 2009.
Australian Patent Examination Report No. 2 for Australian Application No. 2007282068 dated Dec. 17, 2012.
Australian Patent Examination Report No. 2 for Australian Application No. 2007282070 dated Nov. 2, 2012.
Automated Patient Care Following Cardiac Surgery. Nicholas T. Kouchoukos; Louis B. Sheppard; John W. Kirklin, Cardiovascular Clinics, Bol. 3, pp. 110-120, 1971.
Baxter Literature for Flo-Guard®6201 Volumetric Infusion Pump, Copyright 1992, 2 pages.
Baxter Literature for MultiPlex ™ Series 100 Fluid Management System, 4 pages, as submitted Jun. 29, 1988 in U.S. Appl. No. 08/868,913.
Bedder, M. et al., “Cost Analysis of Two Implantable Narcotic Delivery Systems,” Journal of Pain and Symptom Management. vol. 6, No. 6, Aug. 1991. pp. 368-373.
Bio Tek Instruments, Inc. Products Catalog. 32 pages. Apr. 1992.
Blade-Citizen, “Entrepeneur takes Aim at Home Health Care Market,” Dec. 31, 1989, 2 pages.
Block Medical: Growing with Home Infusion Therapy, In Vivio, The Business and Medicine Report, Apr. 1991, 3 pages.
Canadian Office Action for Canadian Application No. 2,659,485 dated Aug. 22, 2013.
Canadian Office Action for Canadian Application No. 2,659,485 dated Mar. 27, 2014.
Canadian Office Action for Canadian Application No. 2,659,494 dated May 12, 2014.
Canadian Office Action for Canadian Application No. 2,659,494 dated Apr. 6, 2017.
Canadian Office Action for Canadian Application No. 2,659,616 dated Jun. 6, 2014.
Canadian Office Action for Canadian Application No. 2,659,618 dated Jun. 16, 2014.
Canadian Office Action for Canadian Application No. 2,659,629 dated May 8, 2014.
Chinese Office Action for Chinese Application No. 201480006387.X dated Apr. 17, 2018.
Communication (Reply to Applicant's Arguments) from Canadian Patent Office for Canadian Application No. 2,659,618 dated Apr. 13, 2015.
Complaint for Patent Infringement (Exhibits 1-3); C.A. No. 03-776, Medtronic Minimed, Inc. v. Deltec Inc., and Smiths Medical Ltd. Aug. 5, 2003.
Computerized Continuous Infusion of Intravenous Anesthetic Drugs During Pediatric Cardiac Surgery; Kern FH, Ungerleider RM, Jacobs JR, Boyd JL 3rd, Reyes JG, Goodman D. Greeley WJ; Department of Anesthesiology, Duke Heart Center, Duke University Medical Center, Durham, North Carolina, Anesth Analg. Apr. 1991; 72(4): 487-92.
Decision of Refusal for Japanese Application No. 2006-542752 dated Jul. 4, 2011.
Decision of Refusal for Japanese Application No. 2006-554321 dated Apr. 18, 2011.
Decision to refuse European Application for European Application No. 07836389.2-2201 dated Dec. 18, 2012.
Decision to refuse European Application for European Application No. 07836379.3-2201 dated Dec. 18, 2012.
Declaration of Anthony C. Roth in Support of Defendant-Counterclaim Plantiff Smiths Medical Md, Inc. 'S Response Brief to Medtronic Minimed, Inc. 'S Claim Construction Brief of U.S. Pat. No. 6,241,704 (Exhibits A-H); C.A. No. 03-776, Medtronic Minimed Inc. v. Smith Medical Md, Inc. Feb. 25, 2005.
Declaration of Anthony C. Roth in Support of Defendant-Counterclaim Plaintiff Smiths Medical Md, Inc. 'S Brief in Opposition of Medtronic Minimed Inc. 'S Motion for Summary Judgment of invalidity of claims 6 and 11 of Smiths Medical Inc. 'S U.S. Pat. No. 6,241,704 (Exhibits 1-7); C,A, No. 03-7769, Medtronic Minimed Inc. v. Smiths Medical Md. Inc. Feb. 28, 2005.
Declaration of non-establishment of ISR for International Application No. PCT/US2009/042494 dated Jan. 5, 2010.
Defendant Smiths Medical Md, Inc. 'S Brief in Opposition to Medtronic Minimed, Inc 'S Motion for Summary Judgment of Invalidity of Claims 6 and 11 of Smiths Medical Inc. 'S U.S. Pat. No. 6,241,704; C.A. No. 03-776, Medtronic Minimed, Inc. v. Smiths Medical Md. Inc. Feb. 28, 2005.
Defendant Smiths Medical Md. Inc. S. Answering Brief Responding to Medtronic Minimed Inc.'S Claim Contruction Brief for U.S. Pat. No. 6,241,704, C.A. No. 03-776, Medtronic Minimed Inc. V. Smiths Medical Md. Inc. Feb. 25, 2005.
Dehne, T., “PC-Based Data Acquisition and Intrumentation,”Analytical Chemistry, vol. 62, No. 9, May 1, 1990. pp. 565A, 566A, 568A, 570A, 571A, 572A.
Dertouzos, M., “Communications, Computers & Net-works,” Scietific American Sep. 1991, pp. 62-69.
Designing the User Interface, Ben Schneiderman, Chapter 5 Direct Manipulation, Oct. 1993, 56 pages.
Devices for Insulin Administration , Jean-Louis Selam, MD and M. Arthur Charles, MD, PhD., Diabetes Care, vol. 13, No. 9, Sep. 1990. pp. 955-979.
Effective Control of Blood Pressure by Computerized Infusion of Sodium Nitroprusside, R.V. Calfee, J.J. Hammond, W.M. Kirkendall, Clinical Research, vol. 25, 1977.
Electronics Feb. 1990 article entitled “Who Will Dominate the Desktop in the '90's?”, 3 pages.
European Office Action for European Application No. 05713999 dated Oct. 30, 2009.
European Office Action for European Application No. 07797060 dated Jul. 3, 2009.
European Office Action for European Application No. 07797060 dated Feb. 9, 2010.
European Office Action for European Application No. 07797060 dated Dec. 8, 2010.
European Office Communication for European Application No. 07810949.3-1662 dated Feb. 25, 2013.
European Office Communication for European Application No. 07836379.3-2201/2050037 dated Jul. 18, 2012.
European Supplementary Partial EP Search Report for EP Application No. EP14743307 dated May 16, 2017.
Examination Report No. 1 for Australian Application No. 2014209383 dated Jul. 20, 2017.
Examination Report No. 2 for Australian Application No. 2014209383 dated Feb. 15, 2018.
Examiner's first report for Australian patent application No. 2007282071 dated Jul. 11, 2011.
Examiner's first report on Australian patent application No. 2007282069 dated Jul. 11, 2011.
Examiner's first report on Australian patent application No. 2007281512 dated Jul. 4, 2011.
Examiner's first report on No. 4 on Australian patent application No. 2005216321 dated Aug. 25, 2011.
Examiner's report No. 2 on patent application No. 2005216321 by Smiths Medical ASD, Inc. dated Jan. 7, 2011. Australian Government IP.
Examiner's report No. 3 on patent application No. 2005216321 by Smiths Medical ASD Inc. dated Apr. 20, 2011, Australian Government IP.
Examiner's first report on patent application No. 2005296794 by Smiths Medical ASD, Inc. dated Dec. 3, 2009. Australian Government IP.
Examiner's first report on patent application No. 2005216321 by Smiths Medical ASD, INC dated Nov. 26, 2009.
Expert Report of Jack Goldberg on behalf of Plaintiff Medtronic Minimed Pursuant to Fed R. Civ. P. 26(A)(2) (Exhibits A-F); C.A. No. 03-776, Medtronic Minimed Inc. v. Smiths Medical Md. Inc. Executed Dec. 15, 2004.
Expert Response of Anthony Storace on behalf of Defendant Counterclaimant Smiths Medical Md., Inc. to The Expert Report Submitted by jack Goldberg on behlaf of Plaintiff Medtronic Minimed (Exhibits B-J); C.A. No. 03-776, Medtronic Minimed Inc. v. Smiths Medical Md, Inc. Jan. 14, 2005.
First Amended Complaint for Patent Infringement (Exhibits 1-3); C.A. No. 03-776, Medtronic Minimed, Inc. v. Deltec Inc. Smiths Group North America Inc. and Smiths Medical Ltd. Nov. 3, 2003.
Fundamentals of Interactive Computer Graphics, Foley et al., Mar. 1993, pp. 10, 11, 29-35.
Greg Sancoff. San Diego Executive, “A Better Mousetrap,” Sep. 1989, 4 pages.
Health Devices, ECRI A Nonprofit Agency, Dec. 1989, vol. 18 No. 12.
Health Devices, ECRI A Nonprofit Agency, Dec. 1991, vol. 20 No. 12.
Health Devices, ECRI A Nonprofit Agency, Sep. 1991, vol. 20, No. 9.
Health Devices, ECRI A Nonprofit Agency, vol. 17 No. 12, Dec. 1988.
Health Devices, ECRI A Nonprofit Agency, vol. 19 Nos. 3-4, Mar.-Apr. 1989.
Hypertensive Crisis Managed by Computer-Controlled Infusion of Sodium Nitroprusside; A Model for the Closed-Loop Administration of Short-Acting Vasoactive Agents. Jeremy J. Hammond, Walter M. Kirkdendall, Richard V. Calfee, Comupters and Biomedical Research, vol. 12, pp. 97-108, 1979.
IMED 980 Volumetric Infusion Pump Operator's Manual. 1992.
IMED STATUS Infusion Management System literature, 6 pages, as submitted Jun. 29, 1988 in U.S. Appl. No. 08/868,913.
Improving Acute Care Use of Medical Device Data, Robert J. Kennelly, Chair, IEEE 1073 “Standard for Medical Device Communications” Committee, Eden Shores Consulting. 1992.
Instruction Manual entitled “Quick Start for Speakerphone XT SVD”, copyright 1996.
Intel® document entitled, 28F001BX-T/28F001BX-B 1M(128Kx8) CMOS Flash Memory, dated Mar. 1991, 28 pages.
International Search Report and Written Opinion for International Application No. PCT/US2004/040397 dated Feb. 7, 2006.
International Search Report and Written Opinion for International Application No. PCT/US2007/017138 dated Nov. 20, 2007.
International Search Report and Written Opinion for PCT/US2007/017120 dated Jan. 25, 2008.
International Search Report for International Application No. PCT/US94/07582 dated Oct. 28, 1994.
International Search Report for International Application No. PCT/US2007/017122 dated Feb. 19, 2008.
International Search Report for International Application No. PCT/US2005/005829 dated Nov. 10, 2005.
International Search Report for International Application No PCT/US2007/017123 dated Jan. 25, 2008.
International Search Report for International Application No. PCT/US2007/017133 dated May 8, 2008.
International Search Report for International Application No. PCT/US2007/022051 dated Mar. 7, 2008.
Intravenous propofol anaesthesia using a computerized infusion system, M. White and G.N.C. Kenny, Anaesthesia, 1990, vol. 45, pp. 204-209.
Invitation to Pay Additional Fees with Partial International Search for International Application No. PCT/US2007/017133 dated Feb. 27, 2008.
Joint Claim Construction Statement (Exhibits 1-2); C.A. No. 03-776, Medtronic Minimed, Inc. v. Smiths Medical Md, Inc. Certificate of service Feb. 4, 2005.
LabVIEW® User Manual, Jan. 1990 Edition, cover page and pp. 2-1 through 2-36.
Lahti W. et al., “Byte”, pp. 311-318, Nov. 1990. “Store Data in a Flash”.
Linkens et al., Computer Control Systems and Pharmacological Drug Administration: A Survey, Journal of Medical Engineering & Technology, vol. 14, No. 2, Mar./Apr. 1990, pp. 41-54.
M68HC11 E Series, HCMOS Microcontroller Unit, Motorola, Inc. 1993, 1996.
McCarthy, LH, Software Simulates Instrumentation Systems, Design News, May 21, 1990, pp. 72-73.
Medtronic MiniMed Paradigm Link Owner's Guide, BD Logic, 2003.
Medtronic Minimed's Reply Brief in Support of it's Motion for Summary Judgment of Non-Infringement of Claims 6 and 11 of Smiths '704 Patent (Exhibits A-B), Medtroni Minimed Inc. v. Smith Medical Md, Inc. Mar. 4, 2005.
Medtronic Minimed's Reply Brief in Support of its Motion for Sumamry Judgment of Invalidilty of Claims 6 and 11 of Smiths '704 Patent (Exhibits A-B); C.A. No. 03-776, Medtronic Minimed Inc. v. Smiths Medical MD, Inc. Mar. 4, 2005.
Memorandum Opinion (Summary Judgment of Infringement of U.S. Pat. No. 5,665,065 and 6,554,798), C.A. No. 03-776, Medtronic Minimed Inc. v. Smiths Medical Md. Inc. Jun. 16, 2005.
Memorandum Opinion: C.A. No. 03-776, Medtronic Minimed, Inc. v. Smiths Medical Md. Inc. Jun. 1, 2005.
Merritt, “Wireless Hospital Health Care Products on the Upswing”. Jan. 7, 2004.
Model 929 Computer Controlled Volumetric Infusion Pump Operating Instructions imed® as submitted Feb. 28, 2008 in U.S. Appl. No. 11/981,788.
National Instruments' 1991 catalog entitled “IEEE-488 and VXlbus Control, Data Acquisition, and Analysis,”cover p. And pp. 1-1 through 1-13, 1-38, 4-68 and 4-69.
National Instruments Document entitled “Scientific Data Analysis,” 16 pages, as submitted Jun. 29, 1988 in U.S. Appl. No. 08/868,913.
National Instruments Instrumentation Newsletter, Aug. 1990, 20 pages. vol. 2, No. 3.
National Instruments Instrumentation Newsletter, Feb. 1991, 20 pages. vol. 3, No. 1.
National Instruments Instrumentation Newsletter, May 1990, 18 pages. vol. 2, No. 2.
National Instruments Instrumentation Newsletter, Nov. 1990, 16 pages. vol. 2, No. 4.
National Instruments Lab Windows 1.2 materials dated Oct. 1989, 5 pages.
National Instruments Lab Windows 2.0 materials, 6 pages, as submitted Jun. 29, 1988 in U.S. Appl. No. 08/868,913.
Notice of Acceptance for Australian Application No. 2007282068 dated Feb. 11, 2014.
Notice of Acceptance for Australian Application No. 2007282070 dated Oct. 3, 2013.
Notice of First Office Action for CN Application No. 201480006387.X dated Dec. 29, 2016. Translation provided.
Notice of Reasons for Rejection for JP Application No. 2015-555273 dated Dec. 5, 2017.
Notification of Reasons for Refusal for Japanese Patent Application No. 2006-542752 dated Jun. 23, 2010.
Notification of Reasons for Refusal for Japanese Patent Application No. 2006-554321 dated Apr. 19, 2010.
Opening Brief in Support of Defendant Smiths Medical, Inc.'S Propsed Claim Contractions for U.S. Pat. Nos. 6,241,704; 6,554,065 and 6,554,798 (Exhibits 1-20); C.A. No. 03-776, Medtronic Minimed, Inc. v. Smiths Medical Md, Inc. Feb. 4, 2005.
Operator's Manual for a CADD-Micro ® Ambulatory Infusion Pump Model 5900, front cover and pp. ii-vi and 1-84, copyright 1993.
Operator's Manual for a CADD-Micro ™Ambulatroy Infusion Pump Model 5400, front cover and pp. ii-vi, pp. 1-55 and two back cover pages, copyright 1990.
Operator's Manual, Gemini ® PC-1 Volumetric Infusion Pump/Controller imed® Aug. 16, 1990.
Order: C.A. No. 03-776; Medtronic Minimed Inc. v. Smiths Medical Md. Inc. Jun. 1, 2005.
Pain Control Devices Gaining Acceptance, Will Expand-Analgesic Delivery Devices-Industry Overview, http://www.findarticles.com/articles/mi_m3498/is_n5_v55/ai_12257770, Sep. 29, 2004.
Patient-controlled Portable Insulin Infusion Pump in Diabetes, Jergen Bojsen, Thorsten Deckert, Klaus Kelendorf, and Birthe Lerup, Diabetes vol. Nov. 28, 1979. Cover page and pp. 974-979.
Peter Lord et al., “MinMed Technologies Programmable Implantable Infusion System, ” pp. 66-91, from Annals of the New York Academy of Sciences, Neurilogical Applications of Implanted Drug Pumps, Copyright 1988.
Principles and Guidelines in Software User Interface Design, Deborah J. Mayhew, Chapter 9 Dialog Sryles: Direct Manipulation, copyright 1992, 17 pages.
Provider® One Instruction Manual, Pancretec, Inc. as submitted on May 18, 1998 in U.S. Appl. No. 08/782,486.
Range Filter Slider Control in Micosoft Excel—Clearly and Simply. Jan. 21, 2013. https://web-beta.archive.org/web/20130121145123/http″//www.cleralyandsimply.com/slearly_and_simply/2011/03range_filter_slider_control_in_microsoft_excel.html retrieved on May 3, 2017.
Second Office Action for Chinese Patent Application No. 201480006387.X dated Sep. 25, 2017. Translation Provided.
Sheppard, L.C., Computerbased Clinical Systems: Automation and Intergration, 39th Annual Conference on Engineering in Medicine and Biology, Baltimore, Maryland, Sep. 13-16, 1986, pp. 73-75.
Singapore Written Opinion for Singapore Application No. 11201505142T dated Mar. 4, 2016.
Steinfeld, Is Embedded Going Net-Crazy?? A Response. Internet Article Mar. 29, 2001.
Steinfeld, Internet-Appliance Technology Automates Test Equipment. pp. 157-169. Oct. 12, 2000.
The Orange County Register No. 21, 1991 article entitled “Portable TV frees patients,” 1 page.
The P1073 Medical Information Bus, David F. Franklin and David V. Ostler (Oct. 1989).
Use of a Microprocessor in the Control of Malignant Hypertension with Sodium Nitroprusside, Jackson RV, Love JB, Parkin WG, Wahlquist ML, Williams NS, Aust N Z J Med. Aug. 1977; 7(4):414-7.
Wilson R., “Integrated Circuits” of Computer Design, pp. 26-27, Jun. 1, 1989.
Written Opinion for International Application No. PCT/US2005/005829 dated Nov. 10, 2005.
Written Opinion for International Application No. PCT/US2007/017122 dated Feb. 19, 2008.
Written Opinion for International Application No. PCT/US2007/017123 dated Jan. 25, 2008.
Written Opinion for International Application No. PCT/US2007/017133 dated May 8, 2008.
Written Opinion for International Application No. PCT/US2007/022051 dated Mar. 7, 2008.
Written Opinion for International Application No. PCT/US2009/042494 dated Jan. 5, 2010.
Zales, S et al., Microprocessors and Microsystems vol. 14, No. 8, pp. 543-549, Oct. 1990.
Application for U.S. Appl. No. 09/631,000, filed Aug. 2, 2000, inventor Blomquist.
Anonymous, “Acute Healthcare Solutions Dosewatch to use Multum's MediSource” PR Newswire Feb. 26, 1998.
Giesen, “Credit Card Terminals Are Growing Up” Credit Card Management. vol. 4, No. 2 May 1991.
Configuring a Network Bridge, Windows server. (2003).
Jovanov et al., “Patient Monitoring Using Person Area Networks of Wireless Intelligent Sensors”, Biomedical Sciences Instrumentation. vol. 37., pp. 373-378. (2001).
www.activejump.com published on Dec. 12, 2002 (as per wayback machine).
Japanese Decision of Refusal for Japanese Application No. 2011-240566 drafting date Dec. 18, 2013.
Canadian OA from Canadian Application No. 2,548,256 dated Apr. 8, 2014.
Australian Examiner's Report No. 3 for Australian Application No. 2011218603 dated Feb. 4, 2014.
Notification of Reasons for Refusal for Japanese Application No. 2011177880 dated Jan. 6, 2014.
Australian Notice of Acceptance for Australian Application No. 2012216290 dated Apr. 3, 2014.
European Communication for European Application No. 05713999.0-1951 dated May 27, 2014.
Canadian Office Action for Canadian Application No. 2552580 dated Jun. 23, 2014.
Canadian OA for Canadian Application No. 2548256 dated Oct. 23, 2012.
European Communication for EP Application No. 04812832.6-1225 dated Oct. 30, 2012.
Canadian OA for Canadian Application No. 2552580 dated Jul. 15, 2013.
Notification of Reasons for Refusal for Japanese Patent Application No. 2011177880 dated Feb. 12, 2013.
European Communication for EP Application No. 090088220-1952 dated Nov. 15, 2013.
Canadian Office Action from Canadian Application No. 2552580 dated Sep. 5, 2012.
User Information CADD-DIPLOMAT™ PC Communications System, 6 pages. © 1998 dated Mar. 1998.
Screen prints from CADD-DIPLOMAT™ PC Communications System CD-ROM, 15 pages. Date unknown.
CADD-DIPLOMAT™ PC Communications System Product Brochure, 4 pages, Jun. 1998.
User Information CADD-DIPLOMAT™ PC Communications System. Nov. 1999.
Application for U.S. Appl. No. 09/920,467, filed Aug. 1, 2001, inventor Blomquist.
Application for U.S. Appl. No. 14/035,071, filed Sep. 24, 2013, inventor Blomquist.
Japanese Notification of Reason for Refusal Japanese Application No. 2014-089162 dated Mar. 9, 2015.
Canadian Office Action for Canadian Application No. 2548256 dated Mar. 31, 2015.
Australian Patent Examination Report No. 1 for AU Patent Applicastion No. 2014200909 dated May 6, 2015.
Application for U.S. Appl. No. 14/035,380, filed Sep. 24, 2013, inventor Blomquist.
Application for U.S. Appl. No. 14/035,510, filed Sep. 24, 2013, inventor Blomquist.
Application for U.S. Appl. No. 14/035,581, filed Sep. 24, 2013, inventor Blomquist.
Chinese Notice of Third Office Action dated Jul. 7, 2014 for Chinese Application No. 200980121204.8. English translation not provided.
Chinese Fourth Office Action for Chinese Application No. 201110092887.8 dated May 14, 2014. English translation not provided.
Australian Patent Examination Report for Australian Patent Appliation No. 2010236098 dated May 20, 2014.
Chinese Office Action for Chinese Application No. 201110092872.1 dated Mar. 25, 2014. English translation not provided.
European Office Action for European Application No. 10189447.5 dated Mar. 12, 2014.
Invitation to Pay Fees and communication relating to the results of the partial Isr for International Application No. PCT/US2009/039178 dated Sep. 3, 2009.
European Office Action for European Application No. 10189449.1 dated Jan. 23, 2014.
Second Chinese Office Action for Chinese Application No. 200980121204.8 dated Oct. 17, 2013. English translation not provided.
Chinese Second Office Action for Chinese Application No. 201110092887.8 dated Mar. 4, 2013. English summary provided.
Chinese Notice of First Office Action for Chinese Application No. 200980121204.8 dated Dec. 18, 2012. English summary provided.
Chinese Notice of First Office Action for Chinese Application No. 201110092872.1 dated Oct. 9, 2012. English summary provided.
Australian Patent Examination Report No. 1 for Australian Application No. 2010236097 dated Nov. 13, 2013.
Australian Patent Examination Report No. 1 for Australian Application No. 2010236098 dated Nov. 14, 2013.
Chinese Notice of Second Office Action for Chinese Application No. 201110092872.1 dated Jul. 10, 2013. English summary provided.
Chinese Notice of First Office Action for Chinese Application No. 201110092887.8 dated Sep. 19, 2012. English summary provided.
European Search Report for European Application No. 10189449 dated Apr. 21, 2011.
European Search Report for European Application No. 10189447 dated May 4, 2011.
Chinese Office Action for Chinese Application No. 201110092887.8 dated Nov. 14, 2013. English summary not provided.
Application for U.S. Appl. No. 11/003,147 dated Dec. 3, 2004, inventor Blomquist.
Rule-based system definition, Text and Image Sources, Contributors and Licenses. Date unknown.
Rule-based Programming definition. Date unknown.
Application for U.S. Appl. No. 13/619,740, filed Sep. 14, 2012, inventor Blomquist.
Canadian Office Action dated Apr. 1, 2016 for Canadian Application No. 2548256.
Application for U.S. Appl. No. 13/619,647, filed Sep. 14, 2012, inventor Blomquist.
Application for U.S. Appl. No. 11/066,425, filed Feb. 2005, inventor Blomquist.
Japanese Decision of Refusal from Japanese Application No. 2011-177880 drafting date Sep. 29, 2014.
Office Action dated Jan. 15, 2018 for Japanese Application No. 2017009980.
AU Patent Examination Report No. 1 for AU Patent Application No. 2014201327 dated Jun. 25, 2015.
Japanese Notification of Reasons for Refusal for JP Application No. 2015021782 drafted Jan. 18, 2016.
Application for U.S. Appl. No. 14/614,551, filed Feb. 5, 2015, inventor Blomquist.
Application for U.S. Appl. No. 14/901,204, filed Dec. 28, 2015, inventors Adam et al.
Huang, Zifang, Prediction of Uterine Contractions Using Knowledge-Assisted Sequential Pattern Analysis, IEEE, © 2011, pp. 1-8.
International Search Report, International Application No. PCT/US2014/044586, dated Oct. 20, 2014, 2 pages.
Notice of Acceptance dated Jul. 9, 2018 for Australian Application No. 2014209383, 3 pages.
Office Action dated Jun. 1, 2018 for Japanese Application No. 2015-555273, 12 pages.
Examination Report dated Dec. 4, 2018 for EP Application No. 14743307.2, 6 pages.
Decision of Dismissal of Amendment dated Mar. 15, 2019 for Japanese Application No. 2015-555273, 6 pages.
Decision of Refusal dated Mar. 15, 2019 for Japanese Application No. 2015-555273, 2 pages.
Office Action dated Sep. 13, 2018 for Japanese Application No. 2015555273, 8 pages.
Office Action dated Nov. 7, 2018 for Chinese Application No. 201480006387.X, 15, pages.
Notice of Acceptance dated Mar. 30, 2020 for Australian Application No. 2018236693, 3 pages.
Office Action dated Dec. 9, 2019 for Canadian Application No. 2,896,100, 4 pages.
Office Action dated Aug. 26, 2020 for Japanese Application No. 2019137279, 6 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC dated Sep. 14, 2020 for EP Application No. 14743307.2, 10 pages.
Related Publications (1)
Number Date Country
20150328396 A1 Nov 2015 US
Provisional Applications (2)
Number Date Country
61757587 Jan 2013 US
61826253 May 2013 US
Continuations (1)
Number Date Country
Parent 14763985 US
Child 14811035 US